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ABSTRACT OF THE DISSERTATION
The Role of Novel Gene UL79 Encoded by Human Cytomegalovirus in Viral Replication
by
Yi-Chieh Perng
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2014
Professor Deborah J Lenschow, Chairperson

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that infects the majority of the
world’s population. Even though HCMV infection is usually asymptomatic, it acts as an
opportunistic pathogen and is the major cause of morbidity and mortality in
immunocompromised individuals, including transplant recipients and AIDS/HIV patients.
Understanding HCMV biology is critical to the development of HCMV therapeutics. However,
our current knowledge of HCMV biology is limited by the fact that only less than half of the
HCMV genes have been characterized, especially viral essential and augmenting genes which
play critical roles in viral replication.
To study the function of HCMV essential and augmenting genes, we devised a conditional
approach to facilitate the analysis. In this approach, we constructed recombinant virus where the
viral open reading frame (ORF) of interest is tagged with the destabilization domain FKBP
(ddFKBP) which targets the fusion protein for rapid degradation. However, the fusion protein
can be stabilized by the synthetic ligand Shield-1 (Shld-1). This system allows us to monitor the
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effects of the viral protein on the HCMV life cycle simply by infecting human fibroblasts in the
presence or absence of Shld-1.
We adopted this conditional protein genetic approach to characterize the role of the human
cytomegalovirus (HCMV) gene UL79 during virus infection. We constructed ADddUL79, a
recombinant HCMV in which the annotated UL79 open reading frame (ORF) was tagged with
ddFKBP. ADddUL79 failed to replicate without Shield-1, but it grew at wild-type levels with
Shield-1 or in human foreskin fibroblasts overexpressing hemagglutinin (HA)-tagged UL79 (HFUL79HA cells), indicating an essential role of UL79 and the effectiveness of this approach.
Without Shield-1, representative immediate-early and early viral proteins as well as viral DNA
accumulated normally, but late transcripts and proteins were markedly reduced. UL79 was
transcribed with early-late kinetics, and was also regulated via a positive-feedback loop. We also
found that the UL79 protein localized to viral replication compartments during HCMV infection.
Moreover, we created a second UL79 mutant virus (ADinUL79stop) in which the UL79 ORF was
disrupted by a stop codon mutation and found that ADinUL79stop phenocopied ADddUL79 under
the destabilizing condition. Taking together, we showed that UL79 acts after viral DNA
replication to promote the accumulation of late viral transcripts.
To test how pUL79 regulates viral late gene transcription, we analyzed the proteome
associated with pUL79 during virus infection by mass spectrometry. We identified both cellular
transcriptional factors, including multiple RNA polymerase II (RNAP II) subunits, and novel
viral transactivators, including pUL87, pUL92, and pUL95, as protein binding partners of
pUL79. Co-immunoprecipitation (co-IP) followed by immunoblot analysis confirmed the
pUL79-RNAP II interaction, and this interaction was independent of any other viral proteins.
We showed that this interaction did not alter the total levels of RNAP II or its recruitment to viral
!
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late promoters. Furthermore, pUL79 did not alter the phosphorylation profiles of the RNAP II
C-terminal domain, which is critical for transcriptional regulation. Rather, nuclear run-on assay
indicated that, in the absence of pUL79, RNAP II failed to elongate and stalled on viral DNA.
Surprisingly, pUL79-dependent RNAP II elongation was required for transcription from all three
kinetic classes of viral genes (i.e. immediate-early, early, and late) at late times during virus
infection. In contrast, host gene transcription during HCMV infection was independent of
pUL79. In summary, we have identified a novel viral mechanism by which pUL79 regulates the
rate of RNAP II transcription machinery on viral transcription during late stages of HCMV
infection.
Together these data provide important insight into how HCMV uses pUL79 to promote
viral transcription specifically during late stages of viral infection. Understanding the
mechanisms by which pUL79 regulates RNAP II elongation as well as its association with other
viral factors will aid in the development of future therapeutics against HCMV infection.
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Chapter 1:

Introduction
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INTRODUCTION
HCMV as human pathogen. Human cytomegalovirus (HCMV), the prototypic βherpesvirus, is a ubiquitous pathogen that infects the majority of the world’s population.
Upon primary infection, HCMV establishes a lifelong persistent and latent/recurrent infection
in a host(12). Even though HCMV infection is usually asymptomatic, it acts as an
opportunistic pathogen and is the major cause of morbidity and mortality in
immunocompromised individuals, including transplant recipients and AIDS/HIV
patients(13). In addition, HCMV is the leading viral cause of birth defects leading to mental
retardation and blindness. Each year, HCMV infects approximately 30,000 newborns,
causing an estimated 400 deaths and 5,000 disabilities in the United States alone(1). The
health and economic impact of HCMV infection is tremendous. The healthcare cost
associated with HCMV-related disease in the United States is estimated at 4 billion dollars
per year(22). Moreover, there is evidence for HCMV to act as a risk factor in the
development of vascular diseases, such as atherosclerosis, transplant vascular sclerosis, and
coronary restenosis after angioplasty surgery(19, 26, 32, 36, 48, 52, 59). Recently, a role for
HCMV has also been implicated in multiple forms of human cancers, where it may contribute
to oncogenic transformation, onco-modulation, and tumor cell immune evasion(6, 16, 23,
42).

HCMV therapeutics. To date, a limited number of drugs are licensed for the treatment of
HCMV infection and no vaccine is available(1). Current standard therapy for HCMV relies
on oral/intravenous ganciclovir (GCV) or its oral prodrug, valganciclovir (VGCV). Although
efficacious, GCV treatment suffers from dose-related toxicities. Forscarnet (FOS) and
cidofovir (CDV), the two commonly used second-line treatments for HCMV, are also
associated with significant toxicities, including renal toxicity. In addition, during
!
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prolonged/repeated application, HCMV can become resistant to GCV and lead to treatment
failure in immunocompromised patients. Of concern, GCV resistance in HCMV infections
has increased during recent years, and the emergence of cross-resistance to either or both
second-line agents (FOS & CDV) is frequently encountered because all licensed drugs share
a common target molecule, the viral DNA polymerase, pUL54(28). Moreover, all current
HCMV antivirals are teratogenic, mutagenic, and potential carcinogens(4, 24, 27, 29). The
dosing limitations due to toxicities further facilitate the emergence of drug-resistance.
Currently no HCMV vaccine is available(1). Therefore, there is an urgent need to develop
new, safe, and efficacious antiviral drugs. A better understanding of HCMV biology, its
interactions with the host, and pathogenesis is critical for us to develop novel and more
effective antiviral therapeutics to control this globally important pathogen.

HCMV biology and reverse genetics. HCMV is the largest known human virus with a
genome of ~240 kb encoding at least 166 annotated viral open reading frames (ORFs)(37, 38)
and several miRNAs(15, 21). The viral genome is composed of a unique long (UL) and a
unique short (US) region with repeated segments at the end of each region, namely TRL/IRL
and TRS/IRS, respectively. ORFs are numbered sequentially in each region. HCMV displays
a lifecycle very similar to other herpesviruses but with a slow replication kinetics, as the virus
does not produce progeny virions until 48-72 hours after infection in primary human
fibroblast cultures in vitro. After binding and internalization, the viral DNA is transported to
the nucleus after which the immediate-early transcripts are expressed. Viral DNA replication
occurs between 24 and 48 hours after infection followed by late gene expression and capsid
assembly. Capsids are then translocated out of the nucleus and acquire their envelope in the
cytoplasm. Once virions are formed they exit the cell beginning around 48 hours post
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infection and continuing for several days until the cell dies(17). The lytic infection cycle of
HCMV is also diagramed in Figure 1.1.
HCMV exhibits strict host specificity as it can only infect human cells. On the other hand,
HCMV can infect a wide range of cell types in its natural host, including epithelial cells,
endothelial cells, smooth muscle cells, fibroblasts, neurons, and macrophages. The virus
spreads systemically via a leukocyte-associated viremia, and the primary infection can
continue for months in adults and years in children. Following the prolonged acute infection
the virus enters a lifelong latent state in lineage- committed myeloid cells and possibly
endothelial cells. The latent virus can then reactivate following differentiation of latently
infected cells into cells permissive for HCMV lytic infection, the reduction in immune
pressure, or due to other unknown determinants(17).
Laboratory-adapted strains of HCMV, such as AD169 and Towne, have been widely used
to study HCMV biology. The laboratory-adapted strains were created by passaging the virus
in fibroblasts for > 100 times in an effort to create a live attenuated vaccine. These strains
replicate efficiently in fibroblasts but inefficiently in other cell types, such as endothelial
cells, epithelial cells, and macrophages(17), which are readily infected by clinical strains of
HCMV. In AD169, this loss in cell tropism can be partially attributed to mutation in the
UL131 genes, as an AD169 variant which has the UL131 gene repaired can efficiently infect
both epithelial and endothelial cells(55, 56). We and others have cloned laboratory strains
(AD169 and Towne)(58), low-passage strain (Toledo), as well as several clinical isolates (TR
and Fix) as infectious bacterial artificial chromosomes (BAC) and developed BAC-based
reverse genetic system for HCMV. The advent of the HCMV reverse genetics greatly
enhances our ability to dissect the molecular mechanisms underlining its biology and
pathogenesis(39).
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Expression kinetics of HCMV genes. During lytic infection, HCMV genes are expressed in
a highly ordered temporal cascade(3, 34, 50, 57). Viral transcripts accumulate with three
kinetic classes, namely immediate-early, early, and late. The HCMV major IE (MIE) genes
UL123 (IE1) and UL122 (IE2) play critical roles in predisposing the cellular environment to
infection and also act as transactivators to induce early gene transcription. Many early genes
encode proteins required for viral DNA synthesis(18, 20, 51). The transcript accumulation of
early genes is independent of viral DNA synthesis; however, the continued accumulation of a
subset of these genes at late times is enhanced by the onset of viral DNA synthesis(49).
Following viral DNA synthesis, late viral genes start to transcribe, which mostly encode
structural proteins required for virus assembly and egress, ultimately leading to the release of
infectious particles. Previous studies have shown that the activation of both beta- and
gamma-herpesvirus late gene promoters is dependent on the origin of viral DNA synthesis
(OriLyt) in cis(2, 14, 35). This further supports the notion that late gene transcription is
tightly coupled to viral DNA synthesis. However, whether viral late gene expression is
subjected to additional viral regulation remains poorly defined.

RNA polymerase II (RNAP II) transcribe HCMV genes. During cytomegalovirus
infection, viral genes are transcribed by cellular RNA polymerase II (RNAP II), a large
multi-subunit enzyme. Rpb1, the largest subunit of RNAP II, has a carboxy terminal domain
(CTD) that contains repeats of the heptapeptide sequence of Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6Ser7(11). The mammalian CTD is compromised of 52 copies of heptapepetides(8). This
unstructured domain is strategically located adjacent to the mRNA exit channel of the
enzyme. This helps the CTD act as a scaffold to coordinate interactions with proteins
involved in different phases of transcription and allow for the coupling of transcription with
other nuclear processes, such as mRNA maturation and chromatin modification(40, 46). The
!
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amino acids within the CTD repeats are targets for post-translational modifications, including
phosphorylation, glycosylation, ubiquitination, and cis-trans isomerization(10). Different
combinations of CTD modifications, known as the CTD codes, orchestrate the sequential
recruitment of numerous factors during the transcription cycle(7).
RNAP II activity is tightly regulated by phosphorylation of its CTD. RNAP II is
recruited to preinitiation complexes (PIC) in an unphosphorylated state(30). Following the
binding of RNAP II to a promoter, serine 5 residue of the CTD (Ser5) is rapidly
phosphorylated by cdk7, the kinase subunit of the transcription factor TFII-H. This facilitates
the dissociation of RNAP II from the PIC(47), and also promotes the recruitment of capping
and splicing factors as well as other histone modification complexes(40). After dissociating
from PIC, RNAP II proceeds to intrinsic pausing sites where it is halted by negative
elongation factors (NELFs). The onset of productive elongation requires the positive
transcription elongation factor P-TEFb composed of cdk9 and cyclin T, which
phosphorylates serine 2 residue (Ser2) of the CTD to produce stable elongation
complexes(31). Ser2 phosphorylation also couples RNA synthesis with RNA processing by
promoting the recruitment of splicing and polyadenylation factors(41). At the 3’ end of the
coding region, RNAP II dissociates from the DNA template and RNA transcript prior to
transcript polyadenylation. Specific phosphatases, Ssu72 and Fcp1, also dephosphorylate the
CTD. Thus, RNAP II is recycled as an unphosphorylated, initiation-competent form for
another round of transcription(9, 25).
HCMV utilizes RNAP II and the accompanying host machinery for transcription of
viral genes. During early times of viral infection, RNAP II and other transcription machinery
are recruited to early replication sites to drive viral IE and early gene expression(53). The
protein levels of RNAP II, including hyper-phosphorylated forms, increase as infection
progresses(53, 54). Treatment of infected cells with cdk inhibitors inhibits viral gene
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expression as well as viral replication(43). During late stages of viral infection, cdk kinase
and RNAP II-associated transcriptional machinery proteins continue to accumulate and
relocate into the peri-replication center(54). However, how RNAP II transcription machinery
remains active on viral loci during late infection requires further investigation.

Functional profile of HCMV genes. Our current knowledge of HCMV biology is limited
by the fact that only less than half of the HCMV genes have been characterized. With the
development of the BAC-based genetic system for HCMV, our group and others have used
global mutagenesis approaches to delineate the functions of the genes encoded by
HCMV(58). These studies led to the creation of a functional genomic map for HCMV strains
AD169 and Towne. In AD169, we identified 3 different classes of genes based on how they
are required for virus growth properties in human foreskin fibroblasts (HFFs) (Figure 1.2).
There were 39 essential gene (mutants that produce no infectious particles), 100 nonessential
genes (mutants that had no growth defect in human fibroblasts), and 27 augmenting genes
(mutants that produced small plaques or had a >10 fold in replication on HFFs(58). Among
66 essential and augmenting viral genes, 25 of them remain uncharacterized and their roles in
HCMV infection are completely unknown. This is because complementing cells that support
growth of null mutants are difficult to obtain for β- and γ- herpesviruses, such as HCMV, and
therefore it is often difficult, if not impossible, to generate recombinant HCMV viruses,
especially the ones defective in essential genes. Currently, only a very few complementing
cell lines have been documented for HCMV mutant viruses(33, 44, 45). As essential and
augmenting genes are critical for efficient virus growth, insight into functions of these genes
is a prerequisite for the rational development of antiviral compounds and vaccine vectors.
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ddFKBP complement system. To study the function of HCMV essential and augmenting
genes, an efficient genetic system is the prerequisite tool. Null mutants of essential genes
produce no progeny and the ones of augmenting genes may have severe growth defects and
produce low viral titers, thus impeding the functional characterization of these genes. The
conventional complementing approach, namely the use of cells expressing mutated gene
products to support growth of null mutants, have been reported for only a very few HCMV
genes because it is difficult to obtain such complementing cells for slowing replicating βherpesviruses(33, 44, 45). Therefore, development of an alternative and efficient
complementation system is necessary for functional studies of HCMV essential and
augmenting genes.
To overcome this hurdle, we devised a conditional approach to facilitate the analysis of
viral proteins critical to viral growth and pathogenesis. A new approach to conditionally
regulate proteins has been established by tagging a protein with a 102-aa unstable variant of
the FKBP12 protein (ddFKBP)(5). In this approach, we construct recombinant virus where
the viral open reading frame (ORF) of interest is tagged with the destabilization domain
FKBP (ddFKBP) which targets the fusion protein for rapid degradation(5). However, the
fusion protein can be stabilized by the synthetic ligand Shield-1 (Shld-1). This system allows
us to monitor the effects of the viral protein on the HCMV life cycle simply by infecting
human fibroblasts in the presence or absence of Shld-1 (Figure 1.3).

Create a library of recombinant HCMV viruses where accumulation of novel essential
and augmenting viral proteins can be regulated by ddFKBP-based protein genetic
approach. Twelve essential genes and 13 augmenting genes for which null mutants have
severe growth defects have not been characterized because of the lack of efficient
complementing system (Table 1.1). We created recombinant HCMVs in which these 25 viral
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genes were tagged with ddFKBP. The 25 genes that were chosen for this study fit two
criteria: 1) these genes are either essential or augmenting for HCMV replication in
fibroblasts; 2) these genes and their homologous in other herpesviruses have not previously
been characterized. Using linear recombination, we constructed 24/25 ddFKBP fusions to
create conditional recombinant viruses for further analysis. (Table 1.1) Recombinant BAC
clones for 10 essential genes and 9 augmenting genes had been electroporated into HFFs to
reconstitute recombinant viruses in the presence of Shld-1. Among these 19 recombinant
viruses, the ones for UL71(ADddUL71), UL77(ADddUL77), UL79(ADddUL79),
UL91(ADddUL91), and UL103(ADddUL103), were efficiently regulated by Shld-1
(Table.1.1). In the presence of Shld-1, these recombinant viruses replicated at wild-type
levels while in the absence of Shld-1 recombinant viruses reconstituted from BAC
transfection were not detected (Growth curves of representative genes shown in Figure 1.4).

Goal of the dissertation. The ddFKBP-based viral genetic system allow us to propagate
recombinant viruses for multiple candidate viral genes, and a prioritization is necessary for us
to select one viral gene for further analysis. Among the five genes that can be regulated by
ddFKBP, UL79 was shown to be required for late stages of viral infection in our preliminary
analysis (Data not shown). HCMV late gene expression is critical to viral replication,
however, how and what viral factors regulate it was completely unknown. Therefore, we
chose UL79 for further analysis. In this dissertation, we characterized the function of UL79
during viral infection and elucidated the mechanism of how it facilitates HCMV gene
expression and viral growth.
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Figure 1.1. Lytic infection cycle of HCMV.
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Fig. 2. Functional map of the HCMV genome. The genome of HCMV strain AD169 is presented as a series of lines with approximate nucleotide sequence
positions indicated to the right of each line. Above the viral genome, solid arrows represent putative ORFs predicted by Davison et al. (3), and open arrows

Figure
Functional
ofannotation
the HCMV
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coloret coded
according
to
represent1.2.
additional
ORFs predicted by Map
the original
of Chee et al.Genome.
(2) and the recent ORFs
reannotation
of Murphy
al. (4). The subset
of mutants from

the BAC library whose growth was analyzed in fibroblasts are positioned on the map below the viral genome, and the nature of each mutation is indicated: Tn5
insertions (TN), Tn1721 insertions (TS), and mutations made by linear recombination (DH). ORFs are color coded according to whether they are essential (blue)
or nonessential (red), or augment (green) replication in fibroblasts. ORFs without an insertion or substitution notation were classified on the basis of earlier
published reports. The terminal repeat long (TRL) sequence and the internal repeat long (IRL) sequence that is identical to the TRL sequence but in the inverted
orientation are indicated as orange arrows on the viral genome. Only the set of ORFs in the TRL region is displayed because the set of ORFs in IRL are identical,
and we did not distinguish which repeat contained the mutations.

whether they are essential (blue) or nonessential (red), or augment (green) replication in

human fibroblasts (HFFs). For essential genes, the electroporated BACs of recombinant
12398 ! www.pnas.org"cgi"doi"10.1073"pnas.1635160100
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HCMV generated GFP-positive cells 2-3 days after electroporation but failed to produce
virus. For augmenting genes, the BACs produced small plaques and/or generated ≥10-fold
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reduced yields of cell-free virus. For nonessential genes, the electroporated BACs produced
normal-sized plaques and virus stocks with wild-type yields(58)
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Figure 1.4. Growth kinetics of the recombinant HCMV in the presence or absence of
Shield-1. Fibroblasts infected with the ADddUL71, ADddUL77, and ADddUL79
recombinant viruses were cultivated with or without 1 µM Shield-1. At the time points
indicated, supernatants were collected and analyzed for the presence of virus by TCID50
assays on fibroblasts maintained in 1 µM Shield-1 (Shld1/Shld1). To test for leakiness of the
system, supernatant of infected cells grown in the absence of Shield-1 was assayed by
TCID50 on cells receiving the Shield-1 ligand (nonShld-1/Shld1). To test the occurrence of
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revertant viruses, both the growth curve and the TCID50 assays were performed in the
absence of Shield-1 (nonShld1/nonShld1).
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TABLES
gene

type

size

UL103

augmenting

28 kDa

ddFKBPtagged
BAC
√

UL71

augmenting

40 kDa

UL91

essential

UL77

Grow like
wt without
Shld-1

BAC DNA
transfected

Regulated
by Shld-1

√

√

√

√

√

12 kDa

√

√

√

essential

71 kDa

√

√

√

UL79

essential

34 kDa

√

√

√

US26

augmenting

66 kDa

√

√

UL27

augmenting

70 kDa

√

√

UL72

augmenting

40 kDa

√

√

UL76

augmenting

36 kDa

√

√

√

UL124

augmenting

17 kDa

√

√

√

UL35

augmenting

71 kDa

√

√

√

UL32

essential

√

√

√

UL49

essential

√

√

√

UL57

essential

115
kDa
63 kDa
136
kDa

√

√

UL92

essential

33 kDa

√

√

√

UL95

essential

59 kDa

√

√

√

UL34

essential

√

√

√

UL87

essential

√

√

√

UL48

augmenting

45 kDa
104
kDa
247
kDa

√

√

√

UL96

essential

14 kDa

√

UL94

essential

38 kDa

√

UL93

essential

65 kDa

√

UL114

augmenting

√

UL47

augmenting

28 kDa
108
kDa

UL30

augmenting

Virus do not
grow with
Shld-1

√
√
√

√

√

12 kDa

Table 1.1. Selected Uncharacterized HCMV Essential and Augmenting Genes
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Chapter 2:

Characterization of HCMV novel essential protein
pUL79 and determine its roles in viral late gene
expression

This chapter contains data published in the following publication
Perng YC, Qian Z, Fehr AR, Xuan B, Yu D. (2011) The human
cytomegalovirus gene UL79 is required for the accumulation of late viral
transcripts. Journal of Virology May;85(10):4841-52.
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ABSTRACT
In this chapter, we adopted a conditional protein genetic approach to characterize the role
of the human cytomegalovirus (HCMV) gene UL79 during virus infection. We constructed
ADddUL79, a recombinant HCMV in which the annotated UL79 open reading frame (ORF)
was tagged with the destabilization domain of a highly unstable variant of the human
FKBP12 protein (ddFKBP). The ddFKBP domain targets the tagged protein for rapid
proteasomal degradation, but the synthetic ligand Shield-1 can stabilize ddFKBP, allowing
accumulation of the tagged protein. ADddUL79 failed to replicate without Shield-1, but it
grew at wild-type levels with Shield-1 or in human foreskin fibroblasts overexpressing
hemagglutinin (HA)-tagged UL79 (HF-UL79HA cells), indicating an essential role of UL79
and the effectiveness of this approach. Without Shield-1, representative immediate-early and
early viral proteins as well as viral DNA accumulated normally, but late transcripts and
proteins were markedly reduced. UL79 was transcribed with early-late kinetics, which was
also regulated via a positive-feedback loop. Using HF-UL79HA cells, we found that the
UL79 protein localized to viral replication compartments during HCMV infection. Finally,
we created a second UL79 mutant virus (ADinUL79stop) in which the UL79 ORF was
disrupted by a stop codon mutation and found that ADinUL79stop phenocopied ADddUL79
under the destabilizing condition. Taking these results together, we conclude that UL79 acts
after viral DNA replication to promote the accumulation of late viral transcripts. Importantly,
the comparative analysis of ADddUL79 and ADinUL79stop viruses provide additional proof
for the power of the protein stability-based conditional approach to dissect the role of viral
factors in HCMV biology.
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INTRODUCTION
Human cytomegalovirus (HCMV) is the prototypical betaherpesvirus and a ubiquitous
opportunistic pathogen that infects the majority of the world's population. Upon primary
infection, HCMV establishes a lifelong persistent and latent/recurrent infection in a host(8).
Even though HCMV infection is usually asymptomatic in healthy individuals, it is a
significant source of severe disease in immunocompromised adults, such as AIDS patients
and transplant recipients. Importantly, HCMV is the leading infectious cause of birth defects
in newborns. Additionally, there is evidence that HCMV is a possible risk factor in the
development of vascular disease, such as atherosclerosis, transplant vascular sclerosis, and
coronary restenosis after angioplasty surgery(15, 24, 31, 35, 40, 42, 57). To acquire a
comprehensive understanding of HCMV biology and facilitate the effort to develop effective
therapeutics to combat disease caused by HCMV, it is imperative to dissect the roles of
previously uncharacterized viral genes in both acute and latent infections of this virus.
During lytic infection, HCMV genes are expressed in a highly ordered temporal cascade.
Viral transcripts accumulate in three different kinetic classes, namely, immediate early (IE),
early, and late. The HCMV major IE (MIE) genes UL123 (IE1) and UL122 (IE2) play a
critical role in predisposing the cellular environment to infection, and they act as
transactivators to induce transcription of early genes. Many early genes encode proteins
involved in viral DNA replication or predisposing the cellular environment to infection(17,
18, 29, 30). The transcript accumulation of early genes is independent of viral DNA
replication; however, the continued accumulation of a subset of genes (i.e., early-late) is
enhanced by the onset of viral DNA replication(41). Following viral DNA replication, late
viral genes that mainly encode structural proteins start to transcribe, ultimately leading to the
assembly and release of infectious particles. Although late gene transcription is tightly
coupled to viral DNA replication, the underlying mechanism is poorly understood.
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HCMV contains a 240-kb double-stranded DNA genome that contains at least 166
putative open reading frames (ORFs) and several microRNAs(7, 15, 17-19, 29, 30).
Previously we and others have used genome-wide mutagenic approaches to classify the entire
set of HCMV genes that encode annotated ORFs into three functional categories(9, 54), and
we found that about 40 genes are essential for the HCMV laboratory strain AD169 to
replicate in human fibroblasts. Many of the HCMV genes have not been experimentally
characterized and lack homologues with known functions in other herpesviruses(33), and
their functions therefore remain elusive. With the advent of the infectious bacterial artificial
chromosome clone-based system for HCMV (BAC-HCMV)(4, 55), the functions of many
HCMV genes have started to be elucidated. However, defining the role of essential genes
remains challenging because of a paucity of a reliable system to propagate null mutant
viruses. The conventional complementation approach, namely, the use of cells expressing a
viral gene in trans to support the growth of the null mutant, has been reported for only a few
essential HCMV genes(33). To overcome this technical hurdle, we and others have recently
adopted a conditional approach(3) to facilitate the analysis of proteins critical to viral growth
and pathogenesis(14, 37). This approach takes advantage of a mutant variant of the human
FKBP12 protein that is highly unstable and rapidly degraded when expressed in mammalian
cells(3). Using this method, a recombinant virus in which a viral ORF of interest is tagged
with the destabilization domain of this FKBP variant (ddFKBP) that confers rapid instability
can be constructed. The addition of the cell-permeable, synthetic ligand Shield-1 stabilizes
the fusion protein, allowing propagation of the recombinant virus. Upon withdrawal of
Shield-1, ddFKBP targets the fusion protein for rapid degradation, thus allowing the study of
the virus infection in the absence of the protein of interest. ddFKBP tagging offers a robust
genetic tool to study the role of viral genes, particularly the ones that are essential for HCMV
infection.
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In this chapter, we characterized the role of viral gene UL79 in HCMV replication. UL79
was previously classified as being essential for HCMV replication in fibroblasts by two largescale mutagenic analyses(9, 54). To define its function during virus replication, we
engineered a recombinant HCMV virus (ADddUL79) in which the annotated UL79 ORF was
tagged with ddFKBP. Using the ddFKBP approach, we found that UL79 was critical for the
accumulation of late viral transcripts but not viral DNA synthesis. This phenotype was
further validated by our analysis of a second UL79 mutant virus in which the UL79 ORF was
disrupted by a stop codon mutation. Furthermore, UL79 was expressed with early-late
kinetics, was regulated by a positive-feedback loop, and primarily localized to viral nuclear
replication compartments during infection.
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MATERIALS AND METHODS
Plasmids, antibodies, and chemicals. pYD-C169 is a retroviral vector derived from pRetroEBNA(23). It was created by inserting a PCR fragment containing the sequence of the UL79
ORF along with a C-terminal hemagglutinin (HA) tag into the multiple cloning site of
pRetro-EBNA. pYD-C630 was derived from pGalK(47) and carried the 110-amino-acid
destabilization domain of the human FKBP12 protein variant that contained the F36V and
L106P destabilizing mutations (ddFKBP)(3). In this vector, ddFKBP was followed by a
GalK/kanamycin dual expression cassette that was flanked by the Flp recognition target
(FRT) sequence.
The primary antibodies used in this study included anti-β-actin (clone AC15; Abcam),
anti-pUL44 (clone 10D8; Virusys), anti-IE2 (MAB8140; Chemicon), anti-HA (H6908;
Sigma), anti-PCNA (clone F-2; Santa Cruz), and anti-FKBP12 (8/FKBP12; BD Biosciences).
Other primary antibodies used in this study were anti-IE1(43), anti-pp28(39), anti-UL38(39),
anti-UL69(25), anti-pp71(6), and anti-pp150 (all generous gifts from Thomas Shenk,
Princeton University). Secondary antibodies used for immunoblotting were horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG and HRP-conjugated goat anti-rabbit IgG
(Jackson Laboratory). The secondary antibodies used for immunofluorescence were Alexa
Fluor 568-conjugated goat anti-rabbit IgG and Alexa Fluor 488-conjugated goat anti-mouse
IgG (Invitrogen-Molecular Probes).
The synthetic chemical ligand Shield-1 (Shld1) that was used to regulate the stability of
ddFKBP-tagged proteins was purchased from Cheminpharma (Farmington, CT).

Cells and viruses. Primary human newborn foreskin fibroblasts (HFFs) and embryonic lung
fibroblasts (MRC5) were propagated in Dulbecco modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum, nonessential amino acids, sodium pyruvate, and
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penicillin-streptomycin. To create HFFs expressing the HA-tagged UL79 (HF-UL79HA
cells) or empty vector (HF-vector cells), retrovirus stocks were prepared from PhoenixAmpho cells(23) that were transfected with the retroviral vector pYD-C169 or pRetroEBNA, respectively. HFFs were transduced with retrovirus three times and then allowed to
recover for 72 h to generate a pool of cells expressing the protein of interest.
Various BAC-HCMV clones were constructed to reconstitute recombinant HCMV
viruses. Two BAC-HCMV clones, pAD/Cre and pAD-GFP, were used as the parental clones
to produce wild-type viruses ADwt.2 and ADwt, respectively. pAD/Cre carries the fulllength genome of HCMV strain AD169, and pAD-GFP is identical to pAD/Cre except that it
contains a simian virus 40 (SV40) early promoter-driven green fluorescent protein (GFP)
gene in place of the viral US4-US6 region(43, 55). All other recombinant BAC clones were
constructed by using a linear recombination protocol in the bacterial strain SW105 that
contained an arabinose-inducible Flp gene for the transient expression of Flp
recombinase(47). To create a BAC clone in which the UL79 ORF was tagged with the
ddFKBP sequence at its N terminus, a cassette that contained the ddFKBP sequence followed
by the GalK/kanamycin dual marker was amplified by PCR from pYD-C630 with a pair of
70-bp primers. The 5’-terminal 50-bp sequences of these primers were homologous to the
viral sequence immediately upstream or downstream of the N terminus of the UL79 ORF (5’TCGTCCATCGTCATTGTCGTCACCGTCGCT
ACCCGCTCACCGAGCGAACGATGGGAGTGCAGGTGGAAACCATC-3’ and 5’TTGCCCGTGCGGACCCGCGGGACGGCGGGGTTCTCTTCGTCGCGGGCCATGCTGG
AGCCACCGCGGGAAGTTC-3’). The cassette was recombined into pAD-GFP at the N
terminus of the UL79 ORF by linear recombination, and the resulting transformants were
selected on kanamycin-containing LB plates to identify clones carrying the marker cassette.
As the GalK/kanamycin marker was also flanked by FRT sites, it was then removed from the
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BAC by adding arabinose to a fresh culture to induce Flp recombinase expression and plating
for isolation of single colonies lacking kanamycin resistance. Therefore, the final clone
(ADddUL79) contained the ddFKBP sequence along with a small FRT site fused in frame at
the N terminus of UL79 (see Figure 2.1A). To create a BAC clone in which the UL79 ORF
was prematurely terminated by a stop codon, a cassette that contained a stop codon followed
by the FRT-bracketed GalK/kanamycin dual marker was amplified by PCR from pYD-C649
with a pair of 70-bp primers. The 5’-terminal 50-bp sequences of these primers were
homologous to the viral sequence immediately upstream or downstream of the 5th amino acid
of the UL79 ORF (5’GTCGTCACCGTCGCTACCCGCTCACCGAGCGAACGATGATGGCCCGCGA
CTGATCACTATAGGGCGAATTGGGTA-3’ and 5’-GTAAAGGAGAATTTGCCC
GTGCGGACCCGCGGGA CGGCGGGGTTCTCTTCAGGGAACAAAAGCTGGA
GCTCC-3’). The cassette was recombined into the UL79 ORF of pAD-GFP, and the
GalK/kanamycin marker was then removed by Flp/FRT recombination as described above
(see Figure 2.7A). The final clone (ADinUL79stop) contained a stop codon along with a small
FRT site inserted in frame at the 6th amino acid codon of the UL79 ORF. All recombinant
BACs were verified by restriction digestion, PCR, and direct sequencing analysis.
To reconstitute virus, 2 µg of the BAC-HCMV DNA and 1 µg of the pp71 expression
plasmid were transfected into HFFs or HF-UL79HA cells by electroporation(55), and the
culture medium was changed 24 h later. For reconstitution of ddFKBP-tagged virus, the
synthetic chemical ligand Shield-1 was added every 48 h to maintain the concentration at 1
µM. The recombinant virus was harvested by collecting cell-free culture supernatant when
the entire monolayer of infected cells was lysed. Virus was amplified by collecting cell-free
culture supernatant from HFFs infected at a multiplicity of infection (MOI) of 0.01 in the
presence of Shield-1. To remove any residual Shield-1, virus-containing culture supernatants
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were then purified by ultracentrifugation through a 20% D-sorbitol cushion at an average
relative centrifugal force of 53,000 × g for 1 h, resuspended in DMEM with 10% fetal calf
serum, and saved as viral stocks. HCMV titers were determined by 50% tissue culture
infectious dose (TCID50) assay. For ddFKBP-tagged virus, the titer was determined in
duplicate in HFFs in the presence of 1 µM Shield-1 (unless indicated otherwise). For
ADinUL79stop virus, the titer was determined in duplicate in HF-UL79HA cells.

Analysis of viral growth kinetics. HFFs, HF-vector cells, or HF-UL79HA cells were
seeded in 12-well plates overnight to produce a subconfluent monolayer. Cells were then
inoculated with recombinant HCMV viruses for 1 h at an MOI of 0.1 for multistep growth
analysis or an MOI of 3 for single-step growth analysis. The inoculum was removed, the
infected monolayers were rinsed with phosphate-buffered saline, and infected cells were
cultured in medium in the presence or absence of Shield-1 (1 µM). To infect cells with virus
in the presence of ligand Shield-1, the ligand was added every 48 h to maintain its
concentration. At various times postinfection, cell-free virus was collected by harvesting the
medium from infected cultures, and the titers of the virus were determined by TCID50 assay.

DNA and RNA analysis. Intracellular viral DNA was measured by quantitative PCR
(qPCR) as previously described(38). HCMV-infected cells were collected at various times
postinfection, resuspended in lysis buffer (200 mM NaCl, 20 mM Tris [pH 8.0], 50 mM
EDTA, 0.2 mg/ml proteinase K, 1% sodium dodecyl sulfate [SDS]), and incubated at 55°C
overnight. DNA was extracted with phenol-chloroform, treated with RNase A (100 µg/ml),
extracted again with phenol-chloroform, precipitated with ethanol, and resuspended in
nuclease-free water (Ambion). Viral DNA was quantified by qPCR as previously described
using a TaqMan probe (Applied Biosystems) and primers specific for the HCMV UL54
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gene(38). Cellular DNA was quantified with SYBR PCR master mix (Clontech) and a
primer pair specific for the human β-actin gene as previously described(38). The
accumulation of viral DNA was normalized by dividing the number of UL54 gene
equivalents by the number of β-actin gene equivalents. The accumulation of wild-type viral
DNA at 4 h postinfection (hpi) was arbitrarily set at 1.
Transcript accumulation was analyzed by reverse transcription coupled to qPCR (RTqPCR) as previously described(53). Total RNA was extracted using the Trizol reagent
(Invitrogen) and treated with the TURBO DNA-free reagent (Ambion) to remove genomic
DNA contaminants. cDNA was reverse transcribed with random hexamer primers using the
high-capacity cDNA reverse transcription kit (Applied Biosystems). For IE1, cDNA was
quantified by qPCR using Maxima probe/Rox 2× qPCR master mix (Fermentas), and a
TaqMan probe (Applied Biosystems) and a primer pair specific for IE1. Alternatively,
cDNA was quantified using SYBR Advantage qPCR premix (Clontech) and primer pairs
specific for viral genes UL32, UL79, UL82, UL93-99, the ddFKBP sequence of ddFKBPUL79, or the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) cellular gene(10, 32,
48). All of the primer pairs and TaqMan probes are listed in Table 2.1. cDNA from infected
cells was used to generate a standard curve for each gene examined. The standard curve was
then used to calculate the relative amount of a specific transcript present in a sample. The
amounts of IE1, UL32, UL79, UL82, and UL93-99 were normalized using GAPDH as an
internal control.

Protein analysis. Protein accumulation and subcellular localization were determined by
immunoblotting and immunofluorescence, respectively. For immunoblotting, cells were
washed with phosphate-buffered saline and lysed in the sodium dodecyl sulfate (SDS)containing sample buffer. Virion proteins were prepared by purifying cell-free virions from
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culture medium of infected cells by ultracentrifugation through a sorbitol cushion and
resuspending the cells in SDS-containing sample buffer. Proteins were resolved by
electrophoresis on an SDS-containing polyacrylamide gel, transferred to a polyvinylidene
difluoride (PVDF) membrane, hybridized with primary antibodies, reacted with the HRPconjugated secondary antibody, and visualized by SuperSignal West Pico chemiluminescent
substrate (Thermo Scientific)(53).
For immunofluorescence, cells grown on glass coverslips were fixed in 2%
paraformaldehyde, permeabilized with 0.1% Triton X-100 for 15 min, incubated with a
primary antibody, and subsequently labeled with an Alexa Fluor 488- or 568-conjugated
secondary antibody (Invitrogen-Molecular Probes). Labeled cells were also counterstained
with TO-PRO-3 (Invitrogen-Molecular Probes) to visualize the nuclei. Finally, labeled cells
were mounted on slides with Prolong Gold antifade reagent (Invitrogen-Molecular Probes).
Images were captured using Zeiss LSM Image software with a Zeiss LSM 510 META
confocal laser scanning microscope.
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RESULTS
Construction of a BAC-HCMV clone carrying the ddFKBP-tagged UL79 and
propagation of recombinant virus. The HCMV UL79 ORF has been reported to be
essential for HCMV replication in fibroblasts(9, 54). To study the function of UL79 in virus
infection, we adopted a protein-based viral genetic approach(3, 14, 37). We constructed a
recombinant BAC-HCMV clone, pADddUL79, in which the annotated UL79 coding
sequence was tagged with a 110-amino-acid destabilization domain derived from a mutant
variant of the human FKBP protein (ddFKBP)(3) at its N terminus (Figure 2.1A). This
recombinant clone was derived from the parental BAC clone (pAD-GFP) which was also
used to reconstitute wild-type virus (ADwt) in this study(55). In cells infected with
recombinant virus (ADddUL79) that was derived from pADddUL79, the ddFKBP-tagged
UL79 protein was anticipated to be expressed but directed for rapid degradation by the
ddFKBP tag. However, the ddFKBP tag should be stabilized in the presence of the synthetic
chemical ligand Shield-1, and therefore, the tagged protein should retain its activity. This
ddFKBP tagging approach offers some unique advantages for creating mutant viruses. It
abrogates protein products of essential genes during virus infection without the need for
creating null mutant virus and complementing cell lines. As only one virus stock is needed
for the comparative study of HCMV infection in the presence or absence of a viral protein
product, it eliminates the need for creating marker rescued virus and avoids the potential
complication resulting from an altered particle-to-PFU ratio in mutant virus. Finally, it
provides evidence that it is the protein encoded by the tagged ORF and not other potential
products derived from the UL79 locus that is important for viral replication.
Transfection of pADddUL79 into human foreskin fibroblasts (HFFs) did not result in any
detectable productive viral infection when the cells were surveyed for 30 days. However,
when Shield-1 was added at a concentration of 1 µM, a cytopathic effect (CPE) was
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observed, similar to that in transfection with wild-type pAD-GFP. Recombinant virus
ADddUL79 produced from pADddUL79 transfection was then amplified by infecting fresh
HFFs in the presence of Shield-1, purified by ultracentrifugation, and resuspended in fresh
medium to generate a virus stock. To confirm that viral growth was dependent on the
presence of Shield-1, HFFs were infected with ADddUL79 at an MOI of 3 with various
concentrations of Shield-1. Infectious culture supernatants were collected at 96 h
postinfection (hpi), and the titer of cell-free virus was determined by TCID50 assay (Figure
2.1B). The rescue of ADddUL79 replication by Shield-1 was dose dependent. While
ADddUL79 failed to produce detectable progeny without Shield-1, its replication and CPE
were indistinguishable from those of the wild-type virus with 1 µM Shield-1 (Figure 2.1B
and C). Our results suggest that Shield-1 efficiently regulates the replication of ADddUL79
recombinant virus.
To provide additional proof that Shield-1 regulated ADddUL79 replication by controlling
the stability of the ddFKBP-tagged UL79 protein, we wanted to examine the expression of
the tagged protein in fibroblasts infected with ADddUL79. Surprisingly, we could not detect
the tagged protein during infection regardless of Shield-1 treatment using an anti-FKBP12
antibody. This was not due to the inability of the antibody to recognize the ddFKBP domain,
because we have used the same antibody to detect other ddFKBP-tagged viral proteins
(Figure 2.10). Moreover, we were able to readily detect the ddUL79 protein from cells
transfected with a plasmid overexpressing ddUL79 in the presence of Shield-1 using the antiFKBP12 antibody (data not shown). Therefore, our inability to detect the tagged protein is
likely the result of the low-level accumulation of the UL79 protein during HCMV infection.
As an alternative approach to confirm that the UL79 ORF encoded a protein essential for
HCMV growth, we tested the growth of ADddUL79 in UL79-overexpressing HFFs (HFUL79HA cells) that were made by transduction of retrovirus carrying the C-terminally HA!
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tagged UL79 ORF. HF-UL79HA cells expressed the tagged protein at the predicted size (35
kDa) (Figure 2.1C). In normal HFFs, ADddUL79 grew like wild-type virus did in the
presence of Shield-1 but could not replicate without it. In contrast, ADddUL79 virus could
replicate in HF-UL79HA cells in the absence of Shield-1, producing virus titers similar to
those of ADwt. Therefore, the growth defect of ADddUL79 in the absence of Shield-1 is the
direct result of the abrogation of UL79.

UL79 is essential for HCMV replication. To characterize the role of UL79 in HCMV
replication, we first analyzed the growth kinetics of the ADddUL79 virus in HFFs. For
progeny virus collected at each time point, we determined the titer of virus in the presence
and absence of Shield-1 to determine whether there were additional escape mutations
acquired during the course of infection. Under the multistep growth condition, ADddUL79
replicated indistinguishably from ADwt in the presence of Shield-1. However, without
Shield-1, the production of ADddUL79 was almost undetectable by 12 days postinfection
(dpi), whereas ADwt growth peaked and the titers reached 1 × 107 TCID50 units/ml (Figure
2.1A). It was noted that at 15 dpi in the absence of Shield-1, ADddUL79 started to produce
very low levels of progeny that could be determined even in the absence of Shield-1. We
interpreted these results to mean that ADddUL79 might acquire spontaneous escape
mutations after a prolonged period under nonpermissive conditions.
Next, we examined the single-step growth kinetics of ADddUL79 to determine whether
the defect was dependent on the MOI. At an MOI of 3 and in the absence of Shield-1,
ADddUL79 produced almost no virus by 4 dpi and very low levels of progeny (<1 × 103
TCID50 units/ml) by 6 dpi, while ADwt reached peak titers of 1 × 107 TCID50 units/ml
(Figure 2.1A). In contrast, Shield-1 treatment restored the growth of ADddUL79 to wildtype levels. The very low levels of ADddUL79 produced after 5 dpi in the absence of Shield!
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1 might be due to the slight leakiness of Shield-1 regulation of ddFKBP degradation(3). It
was unlikely that this low level of virus growth represented escape mutants because they
could not establish a second round of infection without Shield-1, their titers did not increase
over time, and their titers could not be measured without Shield-1.
Taken together, these data indicate that UL79 is essential for HCMV replication in
cultured fibroblasts and that ddFKBP-mediated Shield-1 regulation allows for tight control of
UL79 function during the virus infection cycle.

UL79 is required for viral replication at late stages of infection. To determine when
UL79 is required during the viral replication cycle, we stabilized UL79 protein accumulation
by Shield-1 at various time points and for different lengths of time in infected cells and then
determined the impact of such temporal accumulation of UL79 proteins on virus production.
To determine whether UL79 was required at early times, Shield-1 was added at the onset of
virus infection but was removed from the medium at 24 or 48 hpi. To determine whether
UL79 was required at late times during infection, Shield-1 was added at 24 or 48 hpi. In both
experiments, the titers of virus in the supernatants of infected cells were determined at 120
hpi (Figure 2.2B). When we added Shield-1 as late as 48 hpi, ADddUL79 replication was
indistinguishable from virus grown in the continuous presence of Shield-1. In contrast, when
Shield-1 was present for only the first 48 h during infection, almost no viral progeny were
produced, similar to ADddUL79 infection in the complete absence of Shield-1. Taken
together, these data indicate that UL79 is required for viral replication during the late stages
of viral infection.

UL79 is required for late viral gene expression. To determine which step of the viral
replication cycle was compromised in the absence of UL79, we first examined the viral
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protein accumulation profile in the absence of Shield-1. The accumulation of viral
immediate-early proteins (IE1-72 and IE2-86) or early/early-late proteins (UL38, UL44,
UL69, and pp65) in cells infected with ADddUL79 was not affected (Figure 2.3 and data not
shown). In contrast, the true late proteins, pp28, pp71, and pp150, accumulated at markedly
reduced levels.
To determine whether the reduced late protein accumulation in ADddUL79 infection was
the result of reduced viral late transcript accumulation, we analyzed the IE1 transcript
(control) and late UL32 (pp150), UL82 (pp71), and coterminated UL93-99 transcripts by RTqPCR analysis (Figure 2.4)(10, 32, 48). All transcripts detected were specific and were not
the result of genomic DNA contamination, as mock-infected cells and qPCR reactions done
in the absence of reverse transcriptase failed to produce any products (data not shown). At 24
hpi, late transcripts were barely detectable, whereas the IE1 transcript accumulated to a high
level (data not shown). Importantly, stabilization of UL79 by Shield-1 had no substantial
effects on viral transcript accumulation at this time point (Figure 2.4), consistent with the
observation that UL79 was not required at early times of infection (Figure 2.2B). At 72 hpi,
even though degradation of UL79 had only a small effect on IE1 transcript accumulation, as
the viral DNA synthesis inhibitor phosphonoacetic acid (PAA) did(10), it reduced the
accumulation of late transcripts almost as markedly as PAA did. The levels of late UL32,
UL82, and UL93-99 transcripts when UL79 was absent were 7-, 27-, and 13-fold lower than
the levels when UL79 was present, respectively (Figure 2.4). Together, our results indicate
that UL79 has minimal effect on viral immediate-early and early gene expression but is
critical for the accumulation of late viral transcripts and proteins.

UL79 is dispensable for viral DNA replication. As viral late gene expression is dependent
on viral DNA replication, it was possible that the defect in late gene expression in the
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absence of UL79 was due to a defect in viral DNA replication. Thus, we examined viral
DNA synthesis in the absence of Shield-1 (Figure 2.5A). Surprisingly, the kinetics of viral
DNA replication during ADddUL79 infection in cells in the absence of Shield-1 was
indistinguishable from that of infection of cells in the presence of Shield-1. To confirm that
Shield-1 withdrawal was effective, supernatants from infected culture were collected at 72
hpi and measured for virus production (Figure 2.5B). Infected cells in the absence of Shield1 produced no detectable virus, indicating that UL79 function was indeed abrogated in these
cells. Therefore, we conclude that UL79 acts after viral DNA replication and is specifically
required for the accumulation of late viral transcripts.

The UL79 transcript is expressed with early-late kinetics and is regulated by a positivefeedback loop. To determine the kinetic class of UL79 expression, we analyzed the UL79
transcript accumulation in fibroblasts infected with ADddUL79 by RT-qPCR (Figure 2.6A).
When the UL79 protein was stabilized, the UL79 transcript accumulated abundantly at late
times of infection, and its level at 72 hpi was 5-fold higher than the level at 24 hpi. The
UL79 transcript level was markedly reduced at 72 hpi when infected cells were treated with
PAA, indicating that its transcript accumulation was augmented by viral DNA replication.
However, in the presence of PAA, the accumulation of UL79 transcript was not completely
inhibited, as the UL79 transcript levels increased almost 3-fold from 24 to 72 hpi. Therefore,
as the accumulation of UL79 transcript is markedly enhanced by, but not completely
dependent on viral DNA synthesis, our data suggest that UL79 is an early-late HCMV gene.
However, in the present study, we cannot rule out the possibility that more than one transcript
emanates from the UL79 locus and that our result reflects the combined expression profile of
these transcripts rather than individual species.
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Surprisingly, when UL79 proteins were destabilized, the level of UL79 transcript was
drastically reduced in infected cells at 72 hpi (Figure 2.6A). This suggests a positivefeedback loop for UL79 expression which in turn amplifies the expression of late viral genes.
To provide additional evidence for this autoregulation of UL79 transcription by its protein
products, we tested whether we could enhance endogenous UL79 transcription during
infection of UL79 recombinant virus by providing the UL79 protein in trans. We infected
HFFs expressing the HA-tagged UL79 (HF-UL79HA cells) or empty vector (HF-vector cells)
with ADddUL79 in the absence of Shield-1. This experimental system allowed us to
uncouple the UL79 protein accumulation (provided by HF-UL79HA cells) and endogenous
UL79 transcript accumulation (from the viral genome). The endogenous UL79 transcription
was analyzed by RT-qPCR using a primer pair specific to the ddFKBP sequence. We found
that the accumulation of ddFKBP-UL79 transcripts in infected HF-UL79HA cells markedly
increased at 72 hpi relative to that in infected HF-vector cells. This indicates that, as
anticipated, the UL79 protein enhances the transcription from the UL79 gene locus (Figure
2.6B). Together, these results suggest that efficient transcription of UL79 is positively
regulated by both viral DNA replication and its own protein products.

A UL79 stop codon mutant virus has the same defect as ADddUL79. To provide
additional proof that the defect of ADddUL79 was the direct result of the loss of UL79
function, we created a second UL79 mutant virus, ADinUL79stop. In this recombinant virus,
we inserted a stop codon at residue Glu6 of the UL79 ORF to abrogate the expression of
UL79 protein products (Figure 2.7A). The ADinUL79stop virus could be reconstituted only
from transfection of the BAC clone in HF-UL79HA cells, not by transfection in normal HFFs
or HF-vector cells. The titer of reconstituted mutant virus was comparable to that of wildtype virus (data not shown), and it replicated efficiently in HF-UL79HA cells but completely
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failed to grow in HF-vector cells (Figure 2.7B). These results indicated that loss of UL79
function was solely responsible for the growth defect of ADinUL79stop. Importantly, cells
infected with ADinUL79stop synthesized viral DNA at wild-type levels (Figure 2.7C) and
accumulated the products of IE genes (IE1-72 and IE2-86) and early genes (pUL38 and
pUL44) efficiently but had a marked defect in accumulation of viral late proteins (pp71 and
pp28) during infection (Figure 2.7D). Therefore, the defect of ADinUL79stop phenocopied
that of ADddUL79 under Shield-1 withdrawal, and our results provide further validation for
the power of the protein stability-based conditional approach to dissect the role of viral
factors in HCMV biology.

The HA-tagged UL79 protein is primarily nuclear and localizes in replication
compartments during virus infection. As UL79 is required for the accumulation of late
viral transcripts, it is possible that it is a nuclear protein involved in the regulation of viral
late gene transcription. We first examined the intracellular distribution of UL79 expressed
alone to determine its ability to localize into the nucleus in the absence of any other viral
factors. We used HF-UL79HA cells because there was no antibody specific to UL79
available and because the tagged UL79 was fully functional to complement UL79-deficient
virus (Figure 2.1C). While no appreciable HA staining was present in normal HFFs, the
staining was readily observed in HF-UL79HA cells, predominantly localizing within the
nuclei, suggesting that UL79 proteins are primarily nuclear (Figure 2.8A). Next we
determined whether the UL79 proteins localized to any virus-induced intracellular structures
during infection, particularly replication compartments. These organized intranuclear viral
structures are sites where sets of viral proteins (e.g., pUL44, pUL57, pUL117, and IE2)(1, 36,
38) and cellular proteins (e.g., p53, Nbs1, and Rad50)(12, 26) are recruited to, and viral
activities, including viral DNA synthesis, late gene transcription, and DNA packaging, take
!

39!

place. To test our hypothesis, we examined the localization of the HA-tagged UL79 proteins
expressed from HF-UL79HA cells that were infected with HCMV, as we were not able to
detect tagged UL79 proteins expressed from the endogenous locus of the viral genome during
infection (data not shown). The tagged UL79 proteins formed large intranuclear domains
which colocalized with pUL44, the virus-encoded DNA polymerase accessory protein that
has been used as a marker for replication compartments(36, 38) (Figure 2.8A), indicating that
a major fraction of HA-tagged UL79 proteins is localized in replication compartments.
Importantly, the formation of UL79-containing large intracellular domains appeared to occur
at late times during infection (Figure 2.8B), providing additional evidence that UL79
functions at late times to regulate gene expression.
We noted that the anti-HA antibody also appeared to generate low-level cytoplasmic
staining in some normal HFFs that were infected with HCMV, even though this staining
intensified in infected cells that expressed the tagged UL79 protein (Figure 2.8A). This
cytoplasmic staining colocalized with pp28-containing viral assembly centers (data not
shown). Nonetheless, we decided not to pursue this further, as we could not rule out the
possibility that the cytoplasmic HA staining represents the nonspecific recognition of
assembly centers by anti-HA antibody.

The UL79 protein is not detected in HCMV virions. A proteomics study has previously
shown that a single UL79-derived peptide can be detected in the HCMV virions only by the
sensitive Fourier transform ion cyclotron resonance (FTICR) mass spectrometry, not by the
more traditional liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis,
suggesting that this peptide may represent a nonspecific contaminant(46). To determine
whether the UL79 protein is a tegument protein, we infected HF-UL79HA cells or HF-vector
cells with ADddUL79 in the presence or absence of Shield-1. We then harvested
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supernatants from infected cells at 96 hpi and partially purified cell-free virions by
ultracentrifugation through a sorbitol cushion. These virion samples appeared to be largely
free of contamination of cellular debris, as they did not contain detectable amounts of the
viral IE1 protein or the cellular PCNA protein (Figure 2.9). On the other hand, the major
capsid protein (MCP) was readily detected, and importantly, pUL69, a protein that is present
in the tegument and dense bodies in very small amounts(46, 50), could also be detected in the
virion samples (Figure 2.9). Under these conditions, however, we could not detect the HAtagged UL79 protein in the virion samples, even though it was readily detectable in total
lysate of infected HF-UL79HA cells. Thus, the UL79 protein is unlikely to be a major
component of the HCMV virion. This was consistent with the result that UL79 appeared to
be required only at late stages (i.e., after 48 hpi) (Figure 2.2B) and suggested the important
role of the newly synthesized UL79 protein in promoting the HCMV lytic infection cycle.
Collectively, our data indicate that UL79 plays a key role at late times after viral DNA
replication to regulate the accumulation of late viral transcripts.

!

41!

DISCUSSION
In this study, we applied the ddFKBP-mediated, Shield-1-regulated protein genetic
approach(3) to investigate the role of viral gene UL79 during HCMV replication. Moreover,
we also compared the effectiveness of this approach to the more traditional viral genetic
approach by creating and analyzing the second UL79 mutant virus in which the UL79 ORF
was disrupted by a stop codon mutation (Figure 7). This comparative analysis provides
additional proof for the power of the protein stability-based conditional approach to dissect
the role of viral factors in HCMV biology. Our work represents one of the few studies that
take advantage of this powerful approach to define viral gene functions in HCMV
biology(14, 37). Shield-1 regulation of ddFKBP-tagged UL79 is robust, reversible, and
precisely controlled and validates the role of UL79 as an essential HCMV gene (Figures 2.1
and 2.2). Interestingly, we could not detect ddFKBP-tagged UL79 protein in cells infected
with ADddUL79 even with Shield-1 using an anti-FKBP12 antibody. Nonetheless, the full
complementation of ADddUL79 in the absence of Shield-1 by HFFs overexpressing UL79
provided additional evidence that the defect of ADddUL79 was the direct result of UL79
depletion (Figure 2.1C). Our inability to detect the endogenous UL79 proteins during
infection is likely due to either their extremely low levels of expression or their unstable
nature, similar to other HCMV proteins such as pUL21a(11). Notably, the accumulation of
the HA-tagged UL79 protein overexpressed from transduced HFFs was also reduced during
infection relative to that in mock-infected cells, suggesting that the turnover of UL79 proteins
may be enhanced during infection (Figure 2.1C). A more sensitive antibody or assay will
need to be developed in order to detect and characterize endogenous UL79 proteins during
HCMV infection.
Our systematic dissection of ADddUL79 infection in the absence of Shield-1 allowed us
to define the stage of the infection cycle where UL79 functioned. Shield-1-dependent rapid
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degradation/stabilization of ddFKBP-tagged proteins(3) gave us a tool to define the
requirement of UL79 in HCMV infection in a nearly real-time manner (Figure 2.2B).
Treating infected cells with Shield-1 for the first 48 hpi could not rescue the growth of
recombinant virus, whereas adding Shield-1 at late times, even at 48 hpi, fully restored its
growth (Figure 2.2), suggesting that UL79 was required at late stages of HCMV infection.
Consistent with the timing of its involvement in virus infection, UL79 was expressed with
early-late kinetics (Figure 2.6) and localized into viral replication compartments where viral
DNA replication and late gene transcription took place (Figure 2.8). These spatial and
temporal characteristics of UL79 support its role in regulating the accumulation of viral late
gene products at transcript levels (Figure 2.3, 2.4, and 2.7).
Depletion of UL79 during HCMV infection was able to uncouple viral DNA synthesis and
viral late gene expression, indicating that the former is not sufficient to promote the latter
(Figure 2.4 and 2.5). For many DNA viruses, the temporal regulation of viral gene
expression is a common feature of their lytic infection. For simian virus 40, the large T
antigen plays an essential role in the activation of viral promoters(5, 21), and viral DNA
replication attenuates in trans the repressor of viral late promoters(49, 58). For adenovirus,
both viral trans-acting factors(16, 34) and viral DNA replication(44, 45) are required for its
late gene expression. Viral DNA replication facilitates late gene expression directly(44) or
indirectly by promoting the expression of viral trans-acting factors(16) or recruitment of
cellular transcription factors to late promoters(45).
For herpesviruses, viral late gene expression has been studied mostly with herpes simplex
virus (HSV) and murine gammaherpesvirus 68 (MHV-68). In HSV, DNA replication is
required in cis for activity of late promoters(20, 28). HSV proteins, including ICP4, ICP8,
and ICP27, are necessary for efficient expression of late genes by interacting with the general
transcription machinery(13, 22, 46), and they facilitate the assembly of transcription
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preinitiation complexes(46, 56). In MHV-68, both viral DNA replication (12) and four viral
proteins, ORF18, ORF24, ORF30, and ORF34, are required for late gene expression(2, 51,
52). HCMV UL79, UL87, and UL95 share sequence homology with ORF18, ORF24, and
ORF34, respectively, while ORF30 is conserved only in gamma-herpesviruses(2, 51, 52).
Both UL79 and ORF18 are dispensable for viral DNA replication but are required for the
accumulation of viral late gene products (Figures 2.4 and 2.5)(2), and UL79 also localizes to
viral replication compartments (Figure 2.8). However, UL79 shares only 28% amino acid
identity to ORF18(2) and is transcribed with early-late kinetics (Figure 2.6), whereas ORF18
was identified as an early gene(27). This body of evidence suggests that a general regulatory
principle of late viral gene expression is conserved across the herpesvirus family, but the
precise mechanism may be unique to each herpesvirus.
How does UL79 regulate late viral gene expression? Three possible mechanisms are
responsible for its activity. It is possible that UL79 may modulate the initiation of late viral
gene transcription(2). It may act as a transcription activator, a function reminiscent of
ORF18. However, as in silico analysis did not reveal any significant homology of UL79 to
known transcription factors or conserved DNA binding motif, UL79 may also stimulate late
gene transcription by activating other transcriptional factors or dissociating repressors from
late gene promoters. Alternatively, UL79 may be involved in regulation of chromatin
structures of replicating viral genomes, which may in turn facilitate late viral gene
expression. Finally, it is also possible that UL79 may promote the accumulation of late
transcripts by maintaining their stability. In any event, the temporal expression (i.e., earlylate kinetics) of UL79 may be partially responsible for its involvement in the accumulation of
only the late transcripts and not the early transcripts. The precise mechanism for how UL79
selectively promotes viral late transcripts will be a key question to address in future study.
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How is the expression of UL79 regulated during HCMV infection? UL79 is expressed
with early-late kinetics; its transcripts accumulate even when viral DNA synthesis is
inhibited, but the accumulation is markedly enhanced upon viral DNA synthesis (Figure 2.6).
Importantly, the efficient accumulation of UL79 transcripts also requires the accumulation of
UL79 proteins themselves and is regulated by a positive-feedback loop (Figure 2.6).
Therefore, low-level UL79 expression appears to occur independently of viral DNA
replication. Viral DNA replication may increase the copy number of DNA templates for
UL79 transcription. Perhaps more importantly, any stimulatory effect of viral DNA
replication on UL79 expression is further amplified via this positive-feedback loop.
Therefore, it is sensible to speculate that viral DNA replication acts in cis and UL79 proteins
function in trans to promote their own expression.
In conclusion, we have identified UL79 as a key viral factor bridging viral DNA
replication and late gene expression during HCMV infection. We are investigating potential
interactions of UL79 with cellular proteins or other viral proteins to define its mechanism
during HCMV infection.
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FIG. 7. A mutant virus in which the UL79 ORF has been abrogated by a stop codon mutation has the same defect as ADddUL79.
(A) Schematic diagram for creating recombinant virus ADinUL79stop. A cassette that contained a stop codon followed by the FRT-bracketed
Figure 2.7. A mutant virus in which the UL79 ORF has been abrogated by a stop codon
GalK/kanamycin dual marker was amplified and recombined into the UL79 ORF of the wild-type HCMV BAC clone. The GalK/kanamycin
marker was then removed by Flp/FRT recombination. The final clone, ADinUL79stop, contained a stop codon along with a small FRT site inserted
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(E6X)
of the
UL79 ORF.
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the dashed line. (C) Viral DNA replication of ADinUL79stop. HF-UL79HA cells or HFvector cells were infected with ADinUL79stop at an MOI of 3. Total DNA was isolated at
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FIG. 8. UL79 proteins are primarily nuclear proteins that localize within viral replication compartments during infection. (A) Normal HFFs or
HF-UL79HA cells were either mock infected or infected with the GFP-less wild-type HCMV virus ADwt.2 at an MOI of 0.5. At 72 hpi, the cells
Figure 2.8. UL79 proteins are primarily nuclear proteins that localize within viral
were harvested and examined by confocal immunofluorescence analysis for the localization of UL79 using anti-HA antibody and viral replication
compartments using anti-pUL44 antibody. The cells were also counterstained with TO-PRO3 to visualize the nuclei. Mock-infected HFFs or HFFs
infected with ADwt.2
were used
as a negative control
for theinfection.
detection of(A)
tagged
UL79 proteins
anti-HA antibody.
(B) were
HF-UL79HA cells were
replication
compartments
during
Normal
HFFs orbyHF-UL79HA
cells
either mock infected or infected with ADwt.2 at an MOI of 0.5. At different times postinfection, cells were examined by confocal fluorescence
! replication compartments using anti-pUL44 antibody
56!and UL79 localization using anti-HA antibody. The cells were also
analysis for viral
counterstained with TO-PRO3 to visualize the nuclei. The white arrows indicate viral replication compartments, and the yellow arrows indicate
the localization of a portion of HA staining to viral assembly center-like cytoplasmic structures. Bars, 20 !m.

either mock infected or infected with the GFP-less wild-type HCMV virus ADwt.2 at an MOI
of 0.5. At 72 hpi, the cells were harvested and examined by confocal immunofluorescence
analysis for the localization of UL79 using anti-HA antibody and viral replication
compartments using anti-pUL44 antibody. The cells were also counterstained with TOPRO3 to visualize the nuclei. Mock-infected HFFs or HFFs infected with ADwt.2 were used
as a negative control for the detection of tagged UL79 proteins by anti-HA antibody. (B) HFUL79HA cells were either mock infected or infected with ADwt.2 at an MOI of 0.5. At
different times postinfection, cells were examined by confocal fluorescence analysis for viral
replication compartments using anti-pUL44 antibody and UL79 localization using anti-HA
antibody. The cells were also counterstained with TO-PRO3 to visualize the nuclei. The
white arrows indicate viral replication compartments, and the yellow arrows indicate the
localization of a portion of HA staining to viral assembly center-like cytoplasmic structures.
Bars, 20 µm.
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FigureC.2.10. Immunoblot Analysis of viral ddFKBP Fusion Proteins. Human fibroblast cells
were infected48with
and ADddUL77(B) recombinant viruses at MOI 3.0 in the
96 hpi
hpi ADddUL71(A)
ddFKBP-UL79
presence and absence of 1µM Shield-1.
The cells were harvested at 48 and 96 hours post
ddFKBP-UL79

infection. The accumulations of(long
various
ddFKBP-fusion proteins were analyzed by
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immunoblot analysis using anti-FKBP12 antibody.
Figure 7. Western Blot Analysis of ddFKBP Fusion Protein. Human fibroblast cells were infected with
ADinddFKBP-UL71(A), ADinddFKBP-UL77(B), and ADinddFKBP-UL79(C) recombinant viruses at MOI 3.0 in
the presence and absence of 1µM Shield-1. The cells were analyzed at 48 and 96 hours post infection by
western blot using anti-FKBP antibody.
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TABLE 1. Primers and probes used for RT-qPCR
Transcript

qPCR reaction

6FAM-TAMRA TaqMan probe sequencea

Primer sequence

TaqMan

5$-CAAGTGACCGAGGATTGCAA-3$
5$-CACCATGTCCACTCGAACCTT-3$

UL32

SYBR green

5$-GGTTTCTGGCTCGTGGATGTCG-3$
5$-CACACAACACCGTCGTCCGATTAC-3$

NA

UL79

SYBR green

5$-CCGCACGGGCAAATTCTCCT-3$
5$-TGGTCCGAGACACCCAGGTTGTT-3$

NA

UL82

SYBR green

5$-TGCTGATGTCTGCCGCGGTAC-3$
5$-CGGGCACTGATCCTGACCGG-3$

NA

UL93-99

SYBR green

5$-GTGTCCCATTCCCGACTCG-3$
5$-TTCACAACGTCCACCCACC-3$

NA

ddFKBP-UL79

SYBR green

5$-TGGAAACCATCTCCCCAGGAGA-3$
5$-TCACCTCCTGCTTGCCTAGCAT-3$

NA

GAPDH

SYBR green

5$-CTGTTGCTGTAGCCAAATTCGT-3$
5$-ACCCACTCCTCCACCTTTGAC-3$

NA

a

5$-TCCTGGCAGAACTCGTCAAACAGA-3$

6FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine; NA, not applicable.

Table
2.1
Primers
andandprobes
for RT-qPCR
in Chapter 2.
chloroform,
precipitated
with ethanol,
resuspendedused
in nuclease-free
water
(Ambion). Viral DNA was quantified by qPCR as previously described using a
TaqMan probe (Applied Biosystems) and primers specific for the HCMV UL54
gene (46). Cellular DNA was quantified with SYBR PCR master mix (Clontech)
and a primer pair specific for the human !-actin gene as previously described
(46). The accumulation of viral DNA was normalized by dividing the number of
UL54 gene equivalents by the number of !-actin gene equivalents. The accumulation of wild-type viral DNA at 4 h postinfection (hpi) was arbitrarily set at 1.
Transcript accumulation was analyzed by reverse transcription coupled to
qPCR (RT-qPCR) as previously described (62). Total RNA was extracted using
the Trizol reagent (Invitrogen) and treated with the TURBO DNA-free reagent
(Ambion) to remove genomic DNA contaminants. cDNA was reverse transcribed with random hexamer primers using the high-capacity cDNA reverse
transcription kit (Applied Biosystems). For IE1, cDNA was quantified by qPCR
using Maxima probe/Rox 2" qPCR master mix (Fermentas), and a TaqMan
probe (Applied Biosystems) and a primer pair specific for IE1. Alternatively,
cDNA was quantified using SYBR Advantage qPCR premix (Clontech) and
primer pairs specific for viral genes UL32, UL79, UL82, UL93-99, the ddFKBP
sequence of ddFKBP-UL79, or the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) cellular gene (16, 38, 57). All of the primer pairs and TaqMan probes
are listed in Table 1. cDNA from infected cells was used to generate a standard
curve for each gene examined. The standard curve was then used to calculate the
relative amount of a specific transcript present in a sample. The amounts of IE1,
UL32, UL79, UL82, and UL93-99 were normalized using GAPDH as an internal
control.
Protein analysis. Protein accumulation and subcellular localization were determined by immunoblotting and immunofluorescence, respectively. For immunoblotting, cells were washed with phosphate-buffered saline and lysed in the
sodium dodecyl sulfate (SDS)-containing sample buffer. Virion proteins were
prepared by purifying cell-free virions from culture medium of infected cells by
ultracentrifugation through a sorbitol cushion and resuspending the cells in
SDS-containing sample buffer. Proteins were resolved by electrophoresis on an
SDS-containing polyacrylamide gel, transferred to a polyvinylidene difluoride
(PVDF) membrane, hybridized with primary antibodies, reacted with the HRPconjugated secondary antibody, and visualized by SuperSignal West Pico chemiluminescent substrate (Thermo Scientific) (62).
For immunofluorescence, cells grown on glass coverslips were fixed in 2%
paraformaldehyde, permeabilized with 0.1% Triton X-100 for 15 min, incubated
with a primary antibody, and subsequently labeled with an Alexa Fluor 488- or
568-conjugated secondary antibody (Invitrogen-Molecular Probes). Labeled cells
were also counterstained with TO-PRO-3 (Invitrogen-Molecular Probes) to visualize the nuclei. Finally, labeled cells were mounted on slides with Prolong
Gold antifade reagent (Invitrogen-Molecular Probes). Images were captured
using Zeiss LSM Image software with a Zeiss LSM 510 META confocal laser
scanning microscope.

!

RESULTS

Construction of a BAC-HCMV clone carrying the ddFKBPtagged UL79 and propagation of recombinant virus. The
HCMV UL79 ORF has been reported to be essential for
HCMV replication in fibroblasts (14, 63). To study the function of UL79 in virus infection, we adopted a protein-based
viral genetic approach (3, 20, 45). We constructed a recombinant BAC-HCMV clone, pADddUL79, in which the annotated
UL79 coding sequence was tagged with a 110-amino-acid destabilization domain derived from a mutant variant of the
human FKBP protein (ddFKBP) (3) at its N terminus (Fig.
1A). This recombinant clone was derived from the parental
BAC clone (pAD-GFP) which was also used to reconstitute
wild-type virus (ADwt) in this study (64). In cells infected with
recombinant virus (ADddUL79) that was derived from
pADddUL79, the ddFKBP-tagged UL79 protein was anticipated to be expressed but directed for rapid degradation by the
ddFKBP tag. However, the ddFKBP tag should be stabilized in
the presence of the synthetic chemical ligand Shield-1, and
therefore, the tagged protein should retain its activity. This
ddFKBP tagging approach offers some unique advantages for
creating mutant viruses. It abrogates protein products of essential genes during virus infection without the need for creating null mutant virus and complementing cell lines. As only
one virus stock is needed for the comparative study of HCMV
infection in the presence or absence of a viral protein product,
it eliminates the need for creating marker rescued virus and
avoids the potential complication resulting from an altered
particle-to-PFU ratio in mutant virus. Finally, it provides evidence that it is the protein encoded by the tagged ORF and not
other potential products derived from the UL79 locus that is
important for viral replication.
Transfection of pADddUL79 into human foreskin fibroblasts (HFFs) did not result in any detectable productive viral
infection when the cells were surveyed for 30 days. However,
when Shield-1 was added at a concentration of 1 #M, a cyto-
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ABSTRACT
In this chapter, we identified a unique mechanism in which human cytomegalovirus
(HCMV) protein pUL79 acts as an elongation factor to direct cellular RNA polymerase II for
viral transcription during late times of infection. We and others previous reported that
pUL79 and its homologues were required for viral transcript accumulation after viral DNA
synthesis (28, 52). We hypothesized that pUL79 represented a unique mechanism to regulate
viral transcription at late times during HCMV infection. To test this hypothesis, we analyzed
the proteome associated with pUL79 during virus infection by mass spectrometry. We
identified both cellular transcriptional factors, including multiple RNA polymerase II (RNAP
II) subunits, and novel viral transactivators, including pUL87, pUL92, and pUL95, as protein
binding partners of pUL79. Co-immunoprecipitation (co-IP) followed by immunoblot
analysis confirmed the pUL79-RNAP II interaction, and this interaction was independent of
any other viral proteins. Using a recombinant HCMV virus where pUL79 protein is
conditionally regulated by a protein destabilization domain ddFKBP, we showed that this
interaction did not alter the total levels of RNAP II or its recruitment to viral late promoters.
Furthermore, pUL79 did not alter the phosphorylation profiles of the RNAP II C-terminal
domain, which was critical for transcriptional regulation. Rather, nuclear run-on assay
indicated that, in the absence of pUL79, RNAP II failed to elongate and stalled on viral DNA.
pUL79-dependent RNAP II elongation was required for transcription from all three kinetic
classes of viral genes (i.e. immediate-early, early, and late) at late times during virus infection.
In contrast, host gene transcription during HCMV infection was independent of pUL79. In
summary, we have identified a novel viral mechanism by which pUL79, and potentially other
viral factors, regulates the rate of RNAP II transcription machinery on viral transcription
during late stages of HCMV infection.
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INTRODUCTION
Human cytomegalovirus (HCMV) is the prototypical beta-herpesvirus and a
ubiquitous pathogen in the human population. Upon primary infection, HCMV establishes a
lifelong persistent and latent/recurrent infection in a host (15). Even though HCMV infection
is usually asymptomatic, it acts as an opportunistic pathogen and is the major cause of
morbidity and mortality in immunocompromised individuals, including transplant recipients
and AIDS/HIV patients (16). Importantly, HCMV is the leading infectious cause of birth
defects in newborns (6). Furthermore, there is evidence for HCMV to act as a risk factor in
the development of vascular diseases, such as atherosclerosis, transplant vascular sclerosis,
and coronary restenosis after angioplasty surgery (23, 36, 42, 45, 60, 66, 79). Recently, a
role for HCMV has also been implicated in multiple forms of human cancers, where it may
contribute to oncogenic transformation, onco-modulation, and tumor cell immune evasion (5,
19, 31, 54).
During lytic infection, HCMV genes are expressed in a highly ordered temporal
cascade (reviewed in (3, 43, 62, 72)). Viral transcripts accumulate with three kinetic classes,
namely immediate-early, early, and late. The HCMV major IE (MIE) genes UL123 (IE1)
and UL122 (IE2) play critical roles in predisposing the cellular environment to infection and
also act as transactivators to induce early gene transcription. Many early genes encode
proteins required for viral DNA synthesis (22, 24, 63). The transcript accumulation of early
genes is independent of viral DNA synthesis; however, the continued accumulation of a
subset of these genes at late times is enhanced by the onset of viral DNA synthesis (61).
Following viral DNA synthesis, late viral genes start to transcribe, which mostly encode
structural proteins required for virus assembly and egress, ultimately leading to the release of
infectious particles. Previous studies have shown that the activation of both beta- and
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gamma-herpesvirus late gene promoters is dependent on the origin of viral DNA synthesis
(OriLyt) in cis (2, 17, 44). This further supports the notion that late gene transcription is
tightly coupled to viral DNA synthesis. However, whether viral late gene expression is
subjected to additional viral regulation remains poorly defined.
Recently, we and others have demonstrated that HCMV encodes five essential
proteins, UL79, UL87, UL91, UL92, and UL95, which are required for the expression of
viral late genes after viral DNA synthesis (28, 48, 52). Murine cytomegalovirus (MCMV)
M79 and M92, homologs of HCMV UL79 and M92, respectively, are also required for late
gene expression (9, 10). Homologs of UL79, UL87, UL91, UL92, and UL95 are found in
murine gammaherpesvirus 68 (MHV-68) (ORF18, ORF24, ORF30, ORF31, and ORF34,
respectively), which have been shown to have similar functions (4, 30, 74, 75). Epstein-Barr
virus (EBV) BcRF1, a UL87 homolog, is a novel viral TATA-box binding protein with
greater specificity for a non-classical TATA-box sequence (25, 76). Intriguingly, these
factors are conserved only in beta- and gamma-herpesviruses and have no known
homologues in herpes simplex virus (HSV) (43, 48), suggesting a unique viral regulatory
mechanism shared by these two herpesviral subfamilies. However, the underlying
mechanisms of how these viral factors regulate late gene expression are incompletely
understood.
During cytomegalovirus infection, viral genes are transcribed by cellular RNA
polymerase II (RNAP II), a large multi-subunit enzyme. Rpb1, the largest subunit of RNAP
II, has a carboxy terminal domain (CTD) that contains repeats of the heptapeptide sequence
of Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (14). The mammalian CTD is compromised of 52
copies of heptapepetides (11). This unstructured domain is strategically located adjacent to
the mRNA exit channel of the enzyme. This helps the CTD act as a scaffold to coordinate
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interactions with proteins involved in different phases of transcription and allow for the
coupling of transcription with other nuclear processes, such as mRNA maturation and
chromatin modification (51, 58). The amino acids within the CTD repeats are targets for
post-translational modifications, including phosphorylation, glycosylation, ubiquitination,
and cis-trans isomerization (13). Different combinations of CTD modifications, known as
the CTD codes, orchestrate the sequential recruitment of numerous factors during the
transcription cycle (8).
RNAP II activity is tightly regulated by phosphorylation of its CTD. RNAP II is
recruited to preinitiation complexes (PIC) in an unphosphorylated state (38). Following the
binding of RNAP II to a promoter, serine 5 residue of the CTD (Ser5) is rapidly
phosphorylated by cdk7, the kinase subunit of the transcription factor TFII-H. This facilitates
the dissociation of RNAP II from the PIC (59), and also promotes the recruitment of capping
and splicing factors as well as other histone modification complexes (51). After dissociating
from PIC, RNAP II proceeds to intrinsic pausing sites where it is halted by negative
elongation factors (NELFs). The onset of productive elongation requires the positive
transcription elongation factor P-TEFb composed of cdk9 and cyclin T, which
phosphorylates serine 2 residue (Ser2) of the CTD to produce stable elongation complexes
(40). Serine 2 phosphorylation also couples RNA synthesis with RNA processing by
promoting the recruitment of splicing and polyadenylation factors (53). At the 3’ end of the
coding region, RNAP II dissociates from the DNA template and RNA transcript prior to
transcript polyadenylation. Specific phosphatases, Ssu72 and Fcp1, also dephosphorylate the
CTD. Thus, RNAP II is recycled as an unphosphorylated, initiation-competent form for
another round of transcription (12, 35).
HCMV utilizes RNAP II and the accompanying host machinery for transcription of
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viral genes. During early times of viral infection, RNAP II and other transcription machinery
are recruited to early replication sites to drive viral IE and early gene expression (67). The
protein levels of RNAP II, including hyper-phosphorylated forms, increase as infection
progresses (67, 69). Treatment of infected cells with cdk inhibitors inhibits viral gene
expression as well as viral replication (55). During late stages of viral infection, cdk kinase
and RNAP II-associated transcriptional machinery proteins continue to accumulate and
relocate into the peri-replication center (69). However, how RNAP II transcription
machinery remains active on viral loci during late infection requires further investigation.
In this chapter, we dissected the mechanism of CMV late gene expression by
investigating the proteins that were associated with late transcription regulator pUL79 during
HCMV infection. We found that pUL79 interacted with a panel of viral and host proteins,
including RNAP II, other novel late transcription regulators pUL87, pUL92, and pUL95, as
well as components of the viral DNA replication complex. We delineated the pUL79-RNAP
II interaction and found that pUL79 bound to RNAP II in the nucleus independent of
additional viral factors. Mechanistically, pUL79 did not alter RNAP II protein levels or the
phosphorylation profile of its CTD domain. Instead, in the absence of pUL79, RNAP II
stalled on viral DNA loci, including those of viral immediate-early, early, and late genes, but
not those of host genes, during late times of infection. This resulted in a significantly
diminished elongation rate of RNAP II-driven transcription on viral loci. We conclude that
during late times of infection HCMV induces the formation of a unique transcriptional
machinery in which pUL79 acts as an elongation factor to specifically drive RNAP IImediated transcription on the viral genome.
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MATERIALS AND METHODS
Plasmids and reagents. pYD-C755 (i.e. pLKO) was a pLKO-based lentiviral vector
(also referred as pLKO.DCMV.TetO.mcs in (20), a generous gift from Roger Everett,
University of Glasgow Centre for Viral Research). pYD-C751 (i.e. pLKO-HA-pUL79) was
created by cloning a PCR fragment containing the UL79 coding sequence along with a Nterminal hemagglutinin (HA) tag into the multiple cloning site of pYD-C755. pYD-C744
was derived from pGalK (71), and carried a cassette in which 3×FLAG tag was followed by a
GalK/kanamycin dual expression cassette flanked by the Flp recognition target (FRT)
sequence (49).
The synthetic chemical ligand Shield-1 (Shld1) used to regulate the stability of
ddFKBP-tagged proteins was purchased from Cheminpharma (Farmington, CT). Benzonase
was purchased from EMD Millipore. The following primary antibodies were used in this
study: anti-beta actin (clone AC15, Abcam); anti-FLAG (clone M2, Sigma-Aldrich); antiHA (clone 16B12, Covance; clone 3F10, Roche); anti FKBP12 (clone 8/FKBP12, BD
Biosciences); anti-Rpb1 (clone N-20 from Santa Cruz to detect total Rpb1; or clone 8WG16
from Abcam to detect both total Rpb1 and unphosphorylated CTD form of Rbp1); anti-Rpb2
(S-20, Santa Cruz); anti-Rpb1 phospho-CTD Ser5/Ser2 (clone H-14, Covance); anti-Rpb1
phospho-CTD Ser5 (clone 3E8, Millipore); anti-Rpb1 phospho-CTD Ser2 (ab5095, Abcam);
anti-CDK9 (clone H-169, Santa Cruz); anti-cyclin T1 (clone H-245, Santa Cruz); anti-pUL44
(clone 10D8, Virusys); anti-IE1, anti-pp28, and anti-pp71 (generous gifts from Thomas
Shenk, Princeton University).
Cells and Viruses. Primary human newborn foreskin fibroblasts (HFFs) and HEK293T cells were propagated in Dulbecco modified Eagle medium (DMEM) supplemented
with 10% fetal calf serum, nonessential amino acids, sodium pyruvate, and penicillin!71!
!

streptomycin.
Three HCMV recombinant viruses, ADwt, ADddUL79, and ADflagUL79, were used
in this study. The wildtype virus ADwt was reconstituted from the BAC-HCMV clone
pADwt (also referred as pAD-GFP in the previous study (52)). pADwt carries the full-length
genome of HCMV strain AD169, with the exception that it contains a simian virus 40 (SV40)
early promoter-driven green fluorescent protein (GFP) gene in place of the viral US4-US6
region that are dispensable for viral replication in HFFs (68, 77). ADddUL79 was derived
from ADwt using BAC recombineering, where the pUL79 coding sequence was fused to that
of destabilizing domain ddFKBP (52).
ADflagUL79 was reconstituted from the BAC clone pADflagUL79. This BAC clone
was derived from pADwt, and was constructed by using a linear recombination approach in
the bacterial strain SW105 that contained an arabinose-inducible Flp gene for the transient
expression of Flp recombinase (49). Briefly, the cassette that carried 3×FLAG followed by
the GalK/kanamycin dual marker was first generated by PCR from pYD-C744 with a pair of
70-bp primers, so that the PCR-generated cassette was also flanked by 50-bp viral sequences
immediately upstream or downstream of the 5’-end of the UL79 coding sequence. The
cassette was recombined into pADwt at the 5’-end of the UL79 coding sequence by using
linear recombination. The GalK/kanamycin marker was subsequently removed by Flp-FRT
recombination (49). The final clone pADflagUL79 contained the 3×FLAG sequence along
with a small FRT site fused in frame at the 5’-terminus of the UL79 coding sequence (Figure
3.1A).
To reconstitute virus, 2µg of the BAC-HCMV DNA and 1µg of the pp71 expression
plasmid were transfected into HFF cells by electroporation (77), and the culture medium was
changed 24 hours later. For reconstitution of ADddUL79 virus, Shld1 was added every 48
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hours to maintain the concentration at 1 µM. Reconstituted virus was harvested by collecting
cell-free culture supernatant when the entire monolayer of cells was lysed. To produce virus
stocks, cell-free culture supernatants were collected from HFFs infected at an MOI of 0.01.
Viruses were pelleted by ultracentrifugation through a 20% D-sorbitol cushion at an average
relative centrifugal force of 53,000 × g for 1 hour, resuspended in DMEM with 10% tissue
fetal calf serum, and saved as viral stocks. HCMV titers were determined by 50% culture
infectious dose (TCID50) assay in HFFs (52).
Transient transfection. Four µg of plasmid DNA and 12 µl polyethylenimine (PEI)
(1mg/ml, Polysciences) were mixed with 100 µl OPTI-MEM (Invitrogen) and incubated at
room temperature for 10 minutes. The mixture was then added to 900 µl complete medium
containing 10% fetal calf serum, and applied to 5×106 HEK-293T cells that were seeded one
day before. Cells were incubated for 4 hours before medium was changed.
Analysis of Immunoprecipitation, Mass Spectrometry, and Immunoblot. For
total cell lysates, immunoprecipitation was performed using a protocol modified from
previous studies (56, 64, 65). In brief, HFF cells (5×107) were infected with HCMV
ADflagUL79 or ADwt at a multiplicity of infection (MOI) of 3. At 72 hpi, cells were
collected, rinsed twice with cold phosphate-buffered saline (PBS), and lysed in 2ml EBC2
buffer (50 mM Tris [pH 8.0], 300 mM NaCl, 0.5% NP40) supplemented with protease and
phosphatase inhibitors. Cell lysates were then supplemented with 250 unit (U) Benzonase
nuclease (Millipore), incubated at 4°C for 15 minutes. One aliquot of cell lysates was saved
as the input control and boiled in the LDS sample buffer in the presence of sample reducing
agent (Novex). The remainder was clarified by centrifugation at 10,000 × g at 4°C for 15
minutes. The supernatant was incubated with protein A-dynabeads (Novex) conjugated with
antibody to FLAG (M2) or Rpb1 (N-20) together with an additional 250U of Benzonase at
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4°C overnight. In addition, to confirm the nuclease activity of Benzonase, an aliquot of the
supernatant was analyzed on a 0.8% agarose gel containing 100 µg/ml ethidium bromide for
the detection of DNA/RNA. The following day the beads were washed three times with 1 ml
EBC2 buffer and once with EBC2 buffer without NP40. The immuneprecipitants were
eluted by boiling in reducing sample buffer for 5 minutes. For nuclear extracts,
immunoprecipitation was performed using the Nuclear Complex Co-IP kit according to the
manufacturer’s instructions (Active Motif).
For mass spectrometry analysis, proteins precipitated by anti-FLAG antibody was
resolved on a NuPAGE 4-12% gradient gel (Novex) and subsequently stained using a
ProteoSilver Silver Stain kit (Sigma-Aldrich) according to the manufacturer’s instruction.
Protein bands unique to ADflagUL79-infected sample were extracted. In addition, gel bands
from the ADwt-infected sample with migrating positions corresponding to those of
ADflagUL79-specific bands were also extracted as negative controls. Extracted gel samples
were submitted to the Keck Mass Spectrometry and Proteomics Facility (School of Medicine,
Yale University) for liquid chromatography (LC)-mass spectrometry analysis for protein
identification.
Protein amounts were determined by immunoblot analysis as previously described
(52). In brief, proteins were resolved on an SDS polyacrylamide gel, transferred to a
polyvinylidene difluoride (PVDF) membrane, hybridized with a primary antibody, reacted
with the horseradish peroxidase-conjugated secondary antibody, and visualized using
chemiluminescent substrate (Thermo Scientific).
Chromatin immunoprecipitation (ChIP). The ChIP was performed using the
MAGnify chromatin-immunoprecipitation system (Life Technologies) and reagents provided
in the kit according to the manufacturer’s protocol with modifications. 2×106 HFFs were
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infected with ADddUL79 at an MOI of 3.0 in the presence or absence of Shld1. At 72 hours,
infected cells were washed twice with PBS, trypsinized, and crosslinked with 1%
formaldehyde at room temperature with mixing for 10 minutes. Glycine was added to the
final concentration of 125 mM and incubated at room temperature for 5 minutes to stop the
cross-linking reaction. Cells were collected by centrifugation at 4°C, 200×g for 10 minutes,
washed twice in ice-cold PBS, and lysed in 100 µl lysis buffer with protease inhibitors.
Chromatins were shared into 200-500 bp fragments by cup-horn sonication in ice water at 30second pulse and 60% output with 40-second interval for 70 times (Branson Sonifier 450).
Samples were gently votexed every five sonication cycles and allowed to cool in ice water for
additional 2 minutes. Lysates were cleared by centrifugation (20,000×g, 15 minutes; 4°C)
and stored as 20-µl aliquots. To confirm the size of sheared chromatin fragments, one 20-µl
aliquot was treated with RNase A at 37°C for 1 hour and de-crosslinked by protease K
treatment overnight. DNA was purified and analyzed by agarose gel electrophoresis (data
not shown).
To immunoprecipitate protein-bound chromatin fragments, each 20-µl aliquot was
diluted in dilution buffer with protease inhibitors, and first incubated with 40 µl BSApreblocked protein A/G Dynabeads to pre-clean for 2 hours. Beads were removed, and one
tenth volume of the supernatant was saved as the input sample. The remainder of the
supernatant was incubated with appropriated antibodies to generate protein-antibody
complexes or with IgG (negative control) (Table 3.2) at 4°C for 16 hours. Forty µl BSApreblocked protein A/G Dynabeads (Invitrogen) was added to the samples and incubated at
4°C for another 1.5 hours to immunoprecipitate the complexes. Beads were collected,
washed twice with IP Buffer 1 and three times with IP Buffer 2. Protein-antibody complexes
were eluted from Dynabeads by incubation with reverse crosslinking buffer with proteinase
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K at 55°C for 15 minutes. Dynabeads were removed, and crosslinking of protein-antibody
complexes in the supernatant were reversed by incubation at 65°C for 15 minutes. In
addition, the input sample was also treated with the reverse crosslinking buffer in the same
procedure to reverse crosslinking. Both input and immunoprecipitated DNAs were isolated
by DNA purification on magnetic beads. DNA fragments were quantified by quantitative
real-time PCR (qPCR) using SYBR Select Mix (Invitrogen) kit or Taqman Fast Advanced
Master Mix kit (Invitrogen). The sequences of primers and Taqman probes are listed in
Table 3.3.
Nuclear run-on assay. The protocol of nuclear run-on assay was adapted from
previous studies with modifications (18, 50, 57). 1×107 HFFs were infected with ADddUL79
at an MOI of 3 in the presence or absence of Shld1. At 72 hpi, cells were washed twice with
PBS, trypsinized, collected by centrifugation (4°C, 270×g), and washed twice with cold PBS
again to remove residual calcium and magnesium. To extract nuclei, cell pellets were
resuspended in 4 mL cell lysis buffer (10 mM Tris-HCl, pH 7.2, 3 mM MgCl2, 10 mM NaCl,
150 mM sucrose, and 0.5% NP40) for 5 minutes on ice. Extracted nuclei were collected by
centrifugation (4°C, 170×g) and gently washed with cell lysis buffer to remove NP40. Pellets
were resuspended in 300 µl freezing buffer (50 mM Tris-HCl, pH 8.3, 40% glycerol, 5 mM
MgCl2, and 0.1 mM EDTA), washed once with 1× run-on reaction buffer (20 mM Tris-HCl,
pH 7.5, 10 mM MgCl2, 150 mM KCl, and 20% (v/v) glycerol). To perform run-on assay, 107
nuclei were incubated in 100 µl 1× run-on reaction buffer with ATP, CTP, GTP (0.5 mM
each), and 0.2 mM biotin-16-UTP (Invitrogen) at 29°C for 30 minutes. The reaction was
stopped by snap freezing in liquid nitrogen. As negative controls, run-on reactions were also
performed with UTP instead of biotin-16-UTP. To isolate biotin-labeled run-on transcripts,
streptavidin-coated Dynabeads (Dynabeads MyOne Streptavidin C1, Invitrogen) were
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resuspended in binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 2 M NaCl), and
mixed with an equal volume of run-on transcripts. The samples were incubated at 42 °C for
20 minutes and then at room temperature for 1.5 hours. Beads were collected, and washed
twice with 15% formamide and three times with 2× standard saline citrate (Invitrogen).
Biotinylated RNAs on the beads were reverse transcribed to generate cDNA using Supercript
VILO cDNA Synthesis Kit (Invitrogen), and quantified by reverse transcription-coupled
qPCR (RT-qPCR) analysis. The relative transcript amounts were normalized to those of 18S
rRNA (that is transcribed by RNA polymerase I (RNAP I) so is an unbiased internal control
for RNAP II activity). In addition, total RNA of infected cells was also isolated separately by
TRIzol extraction (Invitrogen) and the amounts were determined by RT-qPCR analysis (see
Table 3.3 for primer sequences).
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RESULTS
Identification of pUL79-interacting proteins
To investigate proteins associated with pUL79, we first generated a recombinant
HCMV in which the UL79 coding sequence was tagged with the 3×FLAG sequence
(ADflagUL79) so that protein complexes containing pUL79 in infected cell lysate could be
isolated by immunoprecipitation (IP) with an anti-FLAG antibody (Figure 3.1A). Both
growth and protein expression profile (Figures 3.1B and 3.1C) of ADflagUL79 was
indistinguishable from those of wildtype AD169 strain (ADwt) in human foreskin fibroblasts
cells (HFFs). These results indicate that the addition of 3×FLAG tag to the N-terminus of the
UL79 coding sequence does not compromise the function of pUL79.
To identify proteins that interacted with FLAG-pUL79, lysates from HFF cells
infected with virus ADflagUL79 or ADwt (negative control) were collected at 72 hours post
infection (hpi) and immunoprecipitated with the anti-FLAG antibody. Immunoprecipitated
proteins were resolved by SDS-PAGE and visualized by silver staining (Figure 3.1D).
Protein bands unique to ADflagUL79 were extracted and their identities were determined by
mass spectrometry. For the negative control, we also extracted gel bands from the ADwt
sample with migrating positions corresponding to those of ADflagUL79-specific protein
bands as negative controls for mass-spectrometry analysis. The full set of proteins that were
identified by this approach and unique to ADflagUL79 is listed in Table 3.1.
These pUL79-interacting proteins could be categorized into several functional groups.
Most notably, four out of twelve core subunits of human RNA polymerase II (RNAP II),
namely Rpb1, Rpb2, Rpb3, and Rpb5, were identified (Table 3.1). Rpb1 is the largest
subunit of RNAP II and its C-terminal domain (CTD) plays a critical role in transcription
regulation by interacting with various transcriptional factors. Second, several viral proteins
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that are conserved among beta- and gamma- herpesviruses, including pUL87, pUL95,
pUL49, and pUL92, were found in the pUL79-protein complexes. pUL87, pUL92, and
pUL95 (shown in Table 3.1), together with pUL79, were required for viral late gene
expression and reported to be recruited to the viral pre-replication complexes(10, 28, 52).
These data together suggest that pUL79 interacts with other viral regulatory proteins involved
in late gene expression during HCMV infection. Third, proteins that were involved in
HCMV DNA synthesis and shown to bind to viral lytic origin of replication (OriLyt) (32),
including pUL44, pIRS1, and pUL112/113, were also found in pUL79 protein complexes.
Copurification of pUL79 and viral DNA replication factors suggests that pUL79 may have a
role in coordinating viral DNA synthesis and late gene expression. Finally, several cellular
proteins involved in protein translation, such as ribosomal protein subunits and elongation
factor 1-alpha1, were co-purified with pUL79.
In the chapter, we focused on the interaction between pUL79 and RNAP II subunits.
As RNAP II transcribes viral genes during infection, we hypothesized that pUL79 interacted
with RNAP II to modify and promote its activity for viral transcription during late times of
infection.

pUL79 interacts with the RNAP II complex
To further investigate the association of the RNAP II complex with pUL79, we first
validated this interaction by immunoprecipitation analysis. HFFs were infected with either
ADflagUL79 or ADwt (negative control), cell lysates were collected at 72 hpi, and proteins
were immunoprecipitated by using antibodies against RNAP II or FLAG, followed by
immunoblot analysis (Figure 3.2). Two RNAP II subunits, Rpb1 and Rpb2, were co!79!
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immunoprecipitated with FLAG-pUL79 but not with ADwt-infected samples (Figure 3.2A).
In a reciprocal experiment, an anti-Rpb1 antibody co-immunoprecipitated not only the RNAP
II complex (indicated by Rpb1 and Rpb2) in both ADflagUL79- and ADwt- infected samples,
but also FLAG-pUL79 in ADflagUL79-infected samples (Figure 3.2B). Taken together,
these results indicate that pUL79 is associated with the RNAP II complex during viral
infection.
The RNAP II complex binds to both DNA and RNA fragments. It was possible that
the observed interaction of pUL79 with RNAP II was indirect, the result of the association of
both proteins with the same DNA or RNA fragment. To determine if nucleic acids were
required for the pUL79-RNAP II interaction, cell lysates were treated with a nonspecific
nuclease (Benzonase) prior to immunoprecipitation (65). Benzonase treatment was effective,
reducing RNA/DNA levels to undetectable levels in ethidium bromide-stained agarose gel
electrophoresis analysis (Figure 3.2A and Figure 3.2B). In the presence of nuclease, pUL79,
Rpb1, and Rpb2 remained co-immunoprecipitated in ADflagUL79-infected lysates (Figure
3.2A and 3.2B). Taken together, these results indicate that pUL79 and RNAP II associate
with one another, and that this association is not mediated by nucleic acids.
We then determined whether the pUL79-RNAP II interaction could form independent
of additional viral factors. To achieve this, we transfected HEK-293T cells with a plasmid
expressing HA-tagged pUL79 or an empty vector plasmid. pUL79 contains a PY-nuclear
localization signal directing it into the nucleus (70) and is located in viral replication
compartments during infection (28, 52). Therefore, we extracted nuclear lysates of
transfected cells, and performed coimmunoprecipitation analysis to examine the pUL79RNAP II interaction using either an anti-HA antibody or anti-Rpb1 antibody in the presence
of nuclease. As anticipated, HA-pUL79 was present in the nuclear extracts (Figure 3.2C and
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3.2D). Anti-HA antibody immunoprecipitated HA-pUL79 together with Rpb1, particularly
the Rpb1 CTD phosphorylated at Serine 2 (pSer2-CTD) (Figure 3.2C). As pSer2-CTD is a
marker of RNAP II undergoing transcriptional elongation, this result suggests that pUL79
may interact with RNAP II during the transcription cycle to modulate its elongation.
Reciprocal coimmunoprecipitation using an anti-Rpb1 further confirmed the association of
RNAP II with pUL79 (Figure 3.2D). Together, these results indicate that pUL79 interacts
with RNAP II independent of other viral factors. The presence of pSer2-CTD in the pUL79RNAP II complex also suggests that pUL79 may regulate the elongation activity of RNAP II.

pUL79 does not alter protein accumulations of RNAP II
A previous study found that HCMV promoted the accumulation of RNA polymerase
II at late times during infection (69). Various isoforms of phosphorylated RNAP II,
including pSer2-CTD and pSer5-CTD (i.e. CTD phosphorylated at Serine 5, a hallmark of
successful transcription initiation) also accumulate at these late times (67, 69). However, the
mechanism of how HCMV regulates these RNAP II-mediated transcriptional events is not
clear.
To test if the pUL79-RNAP II association could stabilize the RNAP II complex to
increase its protein levels, we measured RNAP II protein accumulation during HCMV
infection in the presence or absence of pUL79 protein. We have previously constructed a
recombinant HCMV virus ADddUL79 in which the UL79 coding sequence was tagged with
the highly unstable ddFKBP domain (52). This allowed us to abrogate pUL79 function by
targeting it for rapid degradation, or maintain its function by stabilizing the protein with the
synthetic ligand Shield-1 (Shld1) (52). Here, we infected HFF cells with ADddUL79 in the
presence or absence of Shld1, and analyzed infected cell lysates by immunoblotting at
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various times post infection. In the presence of Shld1, ddFKBP-pUL79 was detected at 72
hpi using the antibody recognizing the ddFKBP epitope, whereas in the absence of Shld1, no
protein was detected (Figure 3.3). To confirm this regulation of pUL79 activity, we also
examined expression profiles of representative viral immediate-early (IE1), early (pUL44),
and late (pp71) proteins. In the presence of pUL79, all three classes of viral proteins were
accumulated with expected kinetics (Figure 3.3). In the absence of pUL79, immediate-early
and early proteins accumulated normally but the accumulation of the late protein was
dramatically reduced (Figure 3.3). These results were consistent with the previous study
(52), and validated the effectiveness of Shld1-mediated regulation of pUL79 activity in this
study. Importantly, the protein levels of Rbp2 and Rpb1 (both total Rpb1 and various CTDphosphor isoforms) increased as expected when infection progressed (67, 69), but the
accumulations were independent of the presence or absence of pUL79 (Figure 3.3).
Together, these results indicate that total RNAP II as well as its CTD modified forms
accumulate during viral infection in a pUL79-independent manner.

pUL79 alters RNAP II occupancy at viral loci
A previous study showed that MHV-68 ORF30 and ORF34, homologues of HCMV
UL91 and UL95, respectively, were required for the recruitment of RNAP II to the viral late
promoters (75). Like ORF30 and ORF34, both UL91 and UL95 were reported to be essential
for late gene expression (28, 48). In this study, we identified pUL95 as a protein partner of
pUL79 (Table 3.1). Therefore, we hypothesized that pUL79 formed a complex with pUL95
and other binding partners to recruit RNAP II to promote assembly of the transcription
initiation complex at viral late promoters.
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To test this, we determined the occupancy of RNAP II on viral late promoters with or
without pUL79 during infection using chromatin immunoprecipitation (ChIP) assay. HFFs
were infected with ADddUL79 in the presence or absence of Shld1, chromatin fractions from
infected cells was collected at 72 hpi and analyzed by ChIP assay using a rabbit anti-RNAP II
antibody. The amounts of input and output (immunoprecipitated) DNA were measured by
quantitative real-time PCR (qPCR) analysis using primers specific to the promoter or
transcript regions of viral genes or cellular housekeeping gene GAPDH (Table 3.3). The
results were presented as relative output-to-input ratios to account for the percentages of
host/viral genomes occupied by RNAP II during viral infection (Figure 3.4). The levels of
viral and cellular DNA immunoprecipitated by Rbp1 antibody were readily detectable
whereas DNA immunoprecipitated by control IgG was minimal, indicating the specific
binding of Rbp1 to the DNA sequences detected in this assay. However, to our surprise, the
occupancy of Rpb1 at promoter or transcript regions of viral genes was not reduced in the
absence of pUL79 (Figure 3.4). Instead, without pUL79, Rpb1 levels on viral DNA were ~22.5 fold higher than those with pUL79. Importantly, during late times of infection (72 hpi),
elevated Rpb1 accumulation occurred not only on the loci of viral late genes (UL32 and
UL75), it also occurred on those of viral immediate-early genes (MIE) and early genes
(UL54) (Figure 3.4). Moreover, this increased association of RNAP II with viral DNA
occurred at both promoter regions and transcript regions. By comparison, Rpb1 occupancy
on the host gene GAPDH was not altered by pUL79. Taken together, these results indicate
that pUL79 regulates the occupancy of RNAP II, but not its recruitment, onto viral loci
during late times of viral infection.
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pUL79 does not alter a particular phosphorylated form of the RNAP II CTD domain
Next we wanted to determine how dysregulated elevation in the occupancy of RNAP
II contributed to its diminished ability to transcribe viral genes when pUL79 was abrogated.
Specifically, we wanted to determine which stage of the RNAP II transcription cycle (i.e.
initiation, elongation, or termination) was altered by pUL79 by ChIP analysis using
antibodies recognizing various forms of RNAP II CTD modifications. In a transcription
cycle, Ser5 of RNAP II CTD is rapidly phosphorylated (pSer5-CTD) to facilitate the
dissociation of RNAP II from the promoter and recruitment of RNA capping and splicing
factors. After that, pSer5 CTD levels decrease with concomitant Ser2 phosphorylation
(pSer2-CTD) to facilitate efficient transcription elongation. At 72 hpi, we found that both
pSer5-CTD and pSer2-CTD levels significantly increased on viral loci in the absence of
pUL79 compared to those in the presence of pUL79 (Figure 3.5A). However, the increase of
unphosphorlyated CTDs on viral loci also paralleled that of phosphorylated CTD (Figure
3.5A). Therefore pUL79 abrogation appeared to elevate all forms of CTD modifications
tested at viral loci.
To more specifically determine whether the elevated accumulation of RNAP II on
viral DNA arose from a specific CTD modification in the absence of pUL79, we normalized
the ChIP occupancy values of pSer5-CTD, pSer2-CTD, and unphosphorylated CTD to that of
total RNAP II. Occupancies of various CTD modifications were proportional to that of total
RNAP II, and we found no evidence for the preferential occupancy of a particular CTD
modification on any viral locus examined (Figure 3.5B). Therefore, elevated RNAP II
occupancy in the absence of pUL79 was unlikely due to the dysregulation of CTD
phosphorylation. Consistently, protein levels of CTD kinases (Cyclin T1 and CDK9) and
CTD phospho-isoforms (pSer2-CTD, pSer5-CTD, pSer5/pSer2-CTD) were not altered by the
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presence or absence of pUL79 (Figure 3.3). These results together indicate that pUL79 is not
involved in phosphorylation of RNAP II CTD, and suggest that without pUL79, RNAP II
simply stalls during the transcription cycle, resulting in its elevated accumulation at viral loci.

pUL79 alters the rate of transcriptional elongation at viral loci
Based on the above results, we hypothesized that pUL79 was required for efficient
elongation of RNAP II-driven transcription at viral loci. To test this, we determined RNAP II
elongation activity using nuclear run-on (NRO) assay. The NRO assay allowed us to
monitored the contribution of RNAP II transcriptional activity to transcript levels
independent of the effect of RNA stability (57). To do this, HFF cells were infected with
ADddUL79 in the presence or absence of Shld1, and the nuclei of infected cells were isolated
and analyzed by NRO assay. Additionally, total RNA was also harvested to monitor the total
transcript accumulation.
We found that in the absence of pUL79, the run-on RNA levels of both MIE and late
genes (UL99 and UL32) were reduced at 72 hpi to approximately 40% of those in the
presence of pUL79 (Figures 3.6A, 3.6D, and 3.6E). The run-on RNA levels of early genes
(UL44 and UL54) without pUL79 were also reduced to approximately 60% of those with
pUL79 (Figures 3.6B and 3.6C). As RNAP II transcribes at the rate of 1.3-4.0 kb/minute
(39), our NRO assay was performed for 30 minutes, long enough for RNAP II to transcribe
all the viral genes tested. However, without pUL79, RNAP II still failed to transcribe viral
genes at the levels comparable to those in pUL79-containing controls. Considering the
increased accumulation of RNAP II at the viral loci in the absence of pUL79, we concluded
that RNAP II requires pUL79 to efficiently elongate on the viral DNA.
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As a control, we also examined the run-on RNA levels of host genes GAPDH and
RPL30 (which encodes a 60S ribosomal protein). Both genes possess a pattern of histone
modifications typical of permissive chromatin, similar to those associated with most CMV
viral loci during late times of infection (47). In contrast to viral genes, the run-on RNA levels
of both GAPDH and RPL30 were not altered by pUL79 (Figures 3.6F-3.6G). This is
consistent with ChIP analysis where the occupancy of RNAP II at GAPDH was found
unaltered in the absence of pUL79 (Figure 3.4), and indicates that RNAP II does not stall at
host genomic loci even without pUL79. Therefore, pUL79 is specifically required for
efficient transcription of viral genes but not host genes.
Taken together, our results from NRO assay provide definitive evidence that pUL79
positively regulates the transcription rates of viral genes but not those of host genes. In the
absence of pUL79, RNAP II may still elongate at viral loci but does so at a much slower pace
at late times, and ultimately fails to support productive viral gene transcription and viral
progeny production.
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DISCUSSION
In this chapter, we discovered a novel regulatory mechanism of viral transcription
mediated by HCMV protein pUL79. We identified cellular RNA polymerase II (RNAP II) as
a key factor that interacted with pUL79. This interaction did not alter the overall
accumulation of total RNAP II or its various phospho-isoforms during viral infection.
Rather, our data suggest that this interaction allowed pUL79 to act as a virus-encoded
elongation factor to stimulate transcriptional elongation activity of RNAP II on viral loci.
Without pUL79, RNAP II elongation failed to proceed efficiently and stalled on the viral
genome. This caused slow turnover and excessive amount of RNAP II accumulation on viral
loci. Ultimately this led to the failure to productive viral late transcription and progeny
production.
This pUL79-mediated regulation occurred at viral loci of all three kinetic classes
(immediate-early, early, and late) at late times during infection. Previously, when total viral
transcripts were analyzed at early times during infection, both immediate-early and early
transcripts accumulated efficiently before pUL79, which was a late protein, could be
expressed (28, 52). Some of these transcripts could be stable and persist until late times of
infection. When overall transcript accumulations were analyzed, the presence of pre-existing
transcripts rendered it difficult to reveal the effect of pUL79 on transcription of immediateearly and early genes at late times during infection. NRO assay could measure relative
transcription elongation rates at specific gene locus at defined times post infection. It
allowed us to show that in fact pUL79 had the potential of driving transcription of many
more viral genes than previously expected during late times of viral infection. A systemic,
global run-on analysis of virally infected cells will further define the scope of viral gene
transcriptions regulated by pUL79.
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How does pUL79 modulate the elongation rate of RNAP II? It is possible that pUL79
enhances promoter clearance, a step in which RNAP II transfers from the initiation state to
the elongation state (Figure 3.7A). During the transcription cycle, RNAP II is recruited to
promoters by cellular TATA-box binding protein (TBP) and other general transcription
factors (GTFs) to form the pre-initiation complexes (PIC). The PIC places RNAP II at
transcription start sites, denatures DNA, and positions DNA into the RNAP II active site for
transcription (7). Once transcription initiates, RNAP II dissociates from PIC and recruits
elongation factors for efficient transcription. The dissociation of RNAP II from PIC is
mediated by TFIIH and other cellular kinases to facilitate exchange between initiation factors
and elongation factors (1, 78). Inefficient dissociation from PIC reduces the rate of RNAP II
elongation, resulting in the failure to transcribe genes (1). Several herpesviral proteins have
been reported to act as viral transcription initiation factors to form a unique viral PIC. For
example, the homologues of HCMV UL87 in gamma-herpesviruses were reported to encode
viral TBPs and regulate late transcript accumulation (2, 25). MHV68 ORF30 and ORF34,
homologues of HCMV UL91 and UL95, were shown to be required for RNAP II recruitment
to viral late promoters (75). EBV Rta, a homolog of CMV UL112/113, was found to
associate with viral late promoters during late times of viral infection (26). These viral
factors might participate in viral PIC assembly by mediating RNAP II promoter positioning.
During HCMV infection, the recruitment of RNAP II to viral promoters was not reduced in
the absence pUL79, suggesting that pUL79 was not required for transcription initiation
(Figure 3.4). However, the elongation rate of RNAP II at viral loci was reduced drastically,
suggesting that pUL79 was essential for a transcription step downstream of initiation (Figure
3.6). Strikingly, pUL79 co-purified with pUL87 and pUL95, two viral factors potentially
involved in viral PIC assembly (Table 3.1). As the viral PIC complex may not be recognized
by host dissociation factors, it is possible that pUL79 plays a role in the release of RNAP II
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from viral PIC prior to elongation (Figure 3.7A). To test this, further analysis is required to
determine the composition of RNAP II/viral PIC as well as their distribution on the viral
DNA.
It is also possible that pUL79 plays a role in epigenetic regulation to modulate viral
transcription (Figure 3.7B). During HCMV infection, viral DNA is chromatinized and
undergoes histone modifications to facilitate gene expression (46). In particular, upon the
onset of viral DNA replication, newly synthesized viral DNA is wrapped with histone 3 with
lysine 4 methylation (H3K4me2), a modification that favors active transcription, suggesting
the potential involvement of epigenetic regulation in viral late transcription (47). Even
though pUL79 was not required for methylating H3K4 (47), the possibility remains that
pUL79 may act as an epigenetic reader to recognize histone modifications unique to viral
DNA, and unwrap viral DNA packaged by histones to facilitate RNAP II elongation (Figure
3.7B).
How does pUL79 specifically regulate transcription of viral loci? In this chapter, we
showed that pUL79-mediated transcriptional regulation was limited to viral but not host
genes (i.e. GAPDH and RPL30). This specificity may be partially due to the localization of
pUL79 during infection as pUL79 is enriched in viral replication compartments where late
viral transcription occurs (52). In addition, late promoters of beta- and gamma-herpesviruses
contain a non-canonical TATA box sequence (25). EBV BcRF1, the homologue of HCMV
pUL87, is a viral TATA-box binding protein which preferentially binds to this non-canonical
TATA box over the canonical sequence. This suggest that viral transcription machinery
directs RNAP II to viral late promoters during late stages of viral infection (25). In HCMV,
several characterized viral late promoters also contain the same non-canonical TATA
sequences (21, 29, 33, 37, 41, 73). Therefore, pUL79 may also act as viral specific TATA!89!
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box binding protein. However, in this chapter, we observed an overall decrease in
transcription rates among all three kinetic classes of viral loci during late times of infection
(Figure 3.6). Further analysis is needed to understand how pUL79 can regulate the rate of
viral transcription regardless of the structures of gene promoters.
In this chapter, we found that pUL79 also co-purified with other viral regulators of
HCMV late gene expression, suggesting that pUL79 may interact with these regulators to
form complexes during viral infection (Table 3.1). It is not known whether these viral
regulators use similar mechanisms to regulate viral transcription. For example, pUL91 and
pUL92 were shown to specifically regulate only true late genes (48). It is possible that these
regulators have conserved functions and yet still possess different specificities. In addition,
pUL79 also co-purified with viral DNA replication factors (Table 3.1). Previously we have
shown that pUL79-mediated viral transcription requires the onset of viral DNA synthesis
(52). Expression of neither pUL79 alone nor the combination of all known late gene
regulators alters the expression kinetics of viral genes, especially viral late genes (48, 52).
Therefore, it is also possible that viral DNA synthesis events predispose viral DNA to late
transcription via interactions between replication factors and pUL79.
In conclusion, we have used a systematic proteomic approach to elucidate the
mechanism underlying the activity of HCMV late gene expression regulator pUL79. pUL79
interacts with RNAP II to modulate its transcription rate at viral loci during late times of viral
infection. This unique viral mechanism is potentially conserved among beta- and gammaherpesviruses, and provides insight into the design of novel antivirals targeting steps after
viral DNA synthesis.
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Figure 3.1. Identification of pUL79 interacting proteins. (A) Schematic diagram for
creating pADflagUL79, the recombinant HCMV BAC clone used to produce virus
ADflagUL79. A cassette that contained a 3×FLAG tag followed by the FRT-bracketed
GalK/kanamycin dual selection marker was amplified by PCR and recombined into the
Figure 1

wildtype HCMV BAC clone (pADwt) at the 5’ terminus of the UL79 coding sequence. The
selection marker was then removed by Flp/FRT recombination. The final clone,
pADflagUL79, carried the UL79 coding sequence tagged at its 5’ terminus with 3×FLAG.
(B) Single step viral growth analysis. HFF cells were infected with HCMV recombinant
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virus ADflagUL79 (derived from pADflagUL79) or ADwt (derived from pADwt) at an MOI
of 3. Infected culture supernatants were collected at indicated days post infection and virus
titers were determined by TCID50 assay. The mean virus titers were derived from two
independent experiments and two technical replicates. Standard deviations were presented.
The detection limit is indicated by the dashed line. (C) Viral protein expression profile.
HFFs were infected as described in (B), and harvested at indicates times post infection.
Accumulations of host and viral proteins were determined by immunoblot analysis. FLAGtagged pUL79 was detected by anti-FLAG antibody. Actin was used as a loading control.
Representative results from three independent experiments are shown. (D) Polyacrylamide
gel electrophoresis to resolve pUL79 protein complexes. HFFs were infected as described in
(B), and at 72 hpi, cell lysates were prepared for immunoprecipitation using an anti-FLAG
antibody. Immunoprecipitated proteins were resolved on a gradient polyacrylamide gel and
silver stained. Protein bands containing RNAP II subunits identified by mass spectrometry
are indicated. Molecular size markers (in kilodaltons) are shown.
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Figure 3.2. pUL79 interacts with the RNAP II protein complex. In (A-B), HFFs were
infected as described in Figure 3.1, and at 72 hpi cell lysates were immunoprecipitated using
either an anti-FLAG antibody (A) or anti-Rpb1 antibody N-20 (B). Immunoprecipitated
proteins and lysate inputs were analyzed by immunoblotting. To examine the efficiency of
nuclease digestion, the immunoprecipitated samples were also analyzed on an ethidium
Figure 2 (EtBr)-stained agarose gel. In (C-D), nuclear lysates from HEK-293T cells
bromide

transiently expressing HA-tagged pUL79 or empty vector control were prepared at 72 hours
post transfection. Lysates were immunoprecipitated using either anti-HA antibody (C) or
anti-Rpb1 antibody 8WG16 (D). Immunoprecipitated proteins and lysate inputs were
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analyzed by immunoblotting. The clone names of antibodies used in immunoblot analysis
are shown. Representative results from three independent experiments are presented.
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Figure 3.3. pUL79 does not alter protein accumulations of RNAP II. HFFs were
infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 µM Shield-1
(Shld1). Cells were harvested at different times post infection and protein accumulation was
analyzed by immunoblot analysis with antibodies recognizing various subunits and isoforms
of RNAP II, cellular CTD kinases (cyclin T1, CDK9), or viral proteins (immediate-early
protein IE1, early-late protein pUL44, late protein pp71). The protein accumulation of the
ddFKBP tagged pUL79 were monitored by an antibody recognizing the FKBP-epitope.
Representative results from three independent experiments are shown.
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Figure 3.4. pUL79 alters RNAP II occupancy at viral loci. HFFs cells were infected with
ADddUL79 at an MOI of 3 in the presence or absence of 1 µM Shld1. Cell extracts were
prepared at 72 hpi and analyzed by ChIP assay using rabbit anti-RNAP II antibody N-20.
Normal rabbit IgG was included as a control for non-specific immunoprecipitation. Amounts
of input and precipitated (output) DNAs were quantified by qPCR with primers specific for
indicated viral loci or human GAPDH. The output-to-input DNA ratios were determined
from four independent ChIP experiments with standard deviations calculated by Prism 6
software. Statistical analysis was performed using Student’s t test (**, P < 0.01; ***, P <
0.005; ****, P < 0.0001; NS, not significant).
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Figure 3.5. pUL79 does not alter a particular phosphorylated form of the RNAP II
CTD domain. HFFs cells were infected with ADddUL79 at an MOI of 3 in the presence or
absence of 1 µM Shld1. Cell extracts were harvested at 72 hpi and analyzed by ChIP assays.
Rabbit antibody to pSer2 CTD, rat antibody to pSer5-CTD, and mouse antibody to nonphosphorylated CTD (8WG16) were used in ChIP assays. Normal rabbit, rat, and mouse
IgGsFigure
were5included as controls for non-specific precipitation, respectively.
Immunoprecipitated DNAs were analyzed as described in Figure 3.4 and the output-to-input
DNA ratios were presented in (A). In addition, the immunoprecipitated amount of each
phosphor-isoform of RNAP II CTD relative to that of total RNAP II (immunoprecipitated
with antibody N-20) was also calculated and presented in (B). Data from four independent
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experiments were collected with standard deviations calculated by Prism 6 software.
Statistical analysis was performed using Student’s t test (*, P < 0.05; **, P < 0.01; ***, P <
0.005).
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Figure 3.6. pUL79 alters the rate of transcriptional elongation at viral loci. HFFs were
infected with ADddUL79 at an MOI of 3 in the presence or absence of 1 µM Shld1 (indicated
Figure 6

by "+" or "-" sign, respectively). Nuclear extracts were prepared at 72 hpi and analyzed by
nuclear run-on (NRO) assays. Transcription elongation was allowed to resume for 30
minutes in the presence of biotin-labeled UTP, labeled RNA was isolated, and their amounts
were determined by RT-qPCR. In addition, accumulations of total RNAs were also
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determined by RT-qPCR. The normalized amounts of viral run-on transcripts or total
transcripts in the presence of Shld1 were set at 1 for run-on assay or total transcript
accumulation analysis, respectively. Relative amounts of total and run-on transcripts for viral
genes MIE (A), UL44 (B), UL54 (C), UL99 (D), UL32 (E), cellular genes GAPDH (F), and
RPL30 (G) were presented. Data from three independent experiments were collected and
standard deviations were calculated by Prism 6 software. Statistical analysis was performed
using Student’s t test (**, P < 0.01; ***, P < 0.005; NS, not significant).
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Figure 3.7. Potential role of pUL79 in RNAP II-mediated viral transcription. During
late times of viral infection where pUL79 is expressed, we propose two models where pUL79
may act as an elongation factor to facilitate viral transcription. (A) In the “promoter
clearance” model, pUL87, pUL92, pUL95, and potentially other viral factors (shown as red
dashed circles) form viral protein pre-initiation complexes (vPIC) to recruit RNAP II to viral
promoters. Once transcription initiates, pUL79 interacts with the vPIC to release RNAP II
from the vPIC for efficient elongation. In the absence of pUL79, RNAP II is unable to
dissociate from vPIC and fails to recruit elongation factors for continued transcription. (B) In
the "epigentic reading" model, pUL79 acts as an epigenetic reader to recognize chromatin
modification(s)
to facilitate RNAP II elongation. During late times of infection, newly
Figure 7
synthesized viral DNA is wrapped with specific histone modifications (shown as purple
dashed ovals). pUL79 recognizes these modifications, and then dissociates viral DNA from
chromatin binding, with or without other cellular/viral factors, to facilitate RNAP II
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elongation. In the absence of pUL79, RNAP II is unable to pass through the unopened
chromatin, resulting in transcriptional stalling on viral loci.
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TABLES

a

Protein ID
Description
HCMV transactivators
pUL87
B8YEB2
pUL95
B8YEB9
pUL92
D2K4K7
pUL79
A8T7F6
HCMV DNA synthesis
UL112/113 (pp34)
Q69214
UL112 (pp84)
D2K4M1
pUL44 (DNA pol. processivity factor)
D2K5E9
IRS1 (tegument protein)
C8CFZ3
Other HCMV proteins
pUL104 (capsid portal protein)
D2K3R0
pUL85 (capsid triplex subunit)
D2K4X8
pUL150 (nuclear egress protein)
D2K4H6
pUL49
Q1KQ04
Cellular RNA polymerase II
Subunit Rpb2
RPB2_Human
Subunit Rpb1
RPB1_Human
Subunit Rpb3
RPB3_Human
Subunit Rpb5
RPB5_Human
Ribosome biogenesis
60S ribosomal protein L7a
RL7A_Human
60S ribosomal protein L21a
RL21_Human
40S ribosomal protein RPS2
RS2_Human
40S ribosomal protein RPS3a
RS3A_Human
60S ribosomal protein RPL23
RL23_Human
60S ribosomal protein RPL23a
RL23A_Human
60S ribosomal protein L24
RL24_Human
40S ribosomal protein S26-like 1
RS26L_Human
Ubiquitin-40S ribosomal protein S27a
RS27A_Human
Other cellular proteins
Actin, cytoplasmic 1
ACTB_Human
Alpha-actinin-1
ACTN1_Human
Elongation factor 1-alpha 1
EF1A1_Human
Annexin A5
ANXA5_Human
Histone H2A type 1-B/E
H2A1B_Human
ATP-dependent DNA helicase Q4
RECQ4_Human

Size (kDa) Expectationa Peptide count
104.7
0
57.2 9.4×10E-37
22.5 6.60×10E-24
33.8 1.5×10E-40

44
26
6
12

28.3
70.2
46.2
91.7

2.7×10E-14
3.2×10E-15
8.0×10E-6
9.6×10E-3

7
6
2
1

78.4
34.5
43.1
63.8

2.5×10E-35
2.8×10E-16
1.1×10E-05
0.01

10
7
2
1

133.8 8.8×10E-101
217 2.6×10E-81
31.4 1.1×10E-20
24.5 6.8×10E-07

29
27
6
2

29.9
18.5
31.3
29.9
14.8
17.6
17.7
12.9
17.9

4.6×10E-07
2.1×10E-11
6.7×10E-05
4.4×10E-04
3.9×10E-04
3.6×10E-04
8.8×10E-01
9.8×10E-03
0.23

3
3
3
3
2
1
1
1
1

41.9
102.9
50.1
35.9
14.12
132.9

4.6×10E-51
8.4×10E-10
4.8×10E-3
9.7×10E-3
0.15
0.25

15
3
3
3
3
1

Expectation value for peptide match (i.e. the number of times expected to obtain an equal or higher score, purely by chance).
A lower value indicates a higher likelihood of the interaction.

Table 3.1. pUL79 protein partners identified by mass spectrometry
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a
b

Antigen

Clone No

Source

Type

Amounta

Dynabeadb

Normal mouse IgG (negative
control)

100005292

Invitrogen

Mouse
polyclonal

2.5 µg

Protein A/G

Normal rabbit IgG (negative
control)

100005291

Invitrogen

Rabbit
polyclonal

1 µg

Protein A/G

Normal rat IgG (negative
control)

NI04

Millipore

Rat
polyclonal

5 µg

Protein G

RNAP II, CTD phosphorylated ab5095
Ser2 (pSer2)

Abcam

Rabbit
polyclonal

1 µg

Protein A/G

RNAP II, CTD phosphorylated 3E8
Ser5 (pSer5)

Millipore

Rat
monoclonal

5 µg

Protein G

RNAP II, unphosphorylated
CTD

8WG16

Abcam

Mouse
monoclonal

2.5 µg

Protein A/G

RNAP II, total

N-20

Santa Cruz

Rabbit
polyclonal

1 µg

Protein A/G

Amount of antibody used in a 2.5×105-cell sample.
Type of Fc-binding proteins conjugated to Dynabeads.

Table 3.2. Antibodies used in chromatin immunoprecipitation assays
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Primer ID

Sequence (5' - 3')

Target

Reference

YD-Pri692
YD-Pri693
YD-Pri744
YD-Pri745
YD-Pri2074
YD-Pri2075
YD-Pri2076
YD-Pri2077
YD-Pri2489
YD-Pri2490
YD-Pri2491
YD-Pri2492
YD-Pri2493
YD-Pri2494
YD-Pri2495
YD-Pri2496
YD-Pri2511
YD-Pri2512
YD-Pri2521
YD-Pri2522
YD-Pri2527
YD-Pri2528
YD-Pri3021
YD-Pri3022
YD-Pri3023
YD-Pri3024
YD-Pri3027
YD-Pri3028
Hs03929097_g1

TTTTCTCACCGAGGAACCTTTC
CCGCTGTTCCCGACGTAAT
CTGTTGCTGTAGCCAAATTCGT
ACCCACTCCTCCACCTTTGAC
GGTTTCTGGCTCGTGGATGTCG
CACACAACACCGTCGTCCGATTAC
GTGTCCCATTCCCGACTCG
TTCACAACGTCCACCCACC
CTTACGGGACTTTCCTACTTG
CGATCTGACGGTTCACTAA
CCTAGTGTGGATGACCTA
GTGACACCAGAGAATCAG
CACCAAAGACACGTCGTT
GTCCTTTGCGACCAGAAT
GTGTGCAACTACGAGGTA
GACAGCACGTTGGTTACA
GGGTGTGGCGCTACGGGTTACAAA
ATGGCTTACCCGCGTGTCCC
GTGTCCATCAAAGAGGATACAG
AAACCACTCCACACGACTGG
CCACGATGGACACCATCATC
AGAAAACCGCGTATCCGCCT
GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
CAAGGCAAAGCGAAATTGGT
GCCCGTTCAGTCTCTTCGATT
CTGGGCAGTTGTTAGCGAGA
GTCGCTGGAGTCGATCAACT
Taqman probe for ChIP (Invitrogen)

UL44, forward
UL44, reverse
GAPDH, forward
GAPDH, reverse
UL32, forward
UL32, reverse
UL99, forward
UL99, reverse
MIE, forward a
MIE, reverse a
MIE, forward
MIE, reverse
UL54, forward a
UL54, reverse a
UL54, forward
UL54, reverse
UL75, forward a
UL75, reverse a
UL75, forward
UL75, reverse
UL32, forward a
UL32, reverse a
18s rRNA, forward
18s rRNA, reverse
RPL30, forward b
RPL30, reverse b
RPL30, forward c
RPL30, reverse c
GAPDH

(27)
(27)
(52)
(52)
(52)
(52)
(52)
(52)
(46)
(46)
(46)
(46)
(46)
(46)
(46)
(46)

a

Promoter regions
Used in RT-qPCR for nuclear run-on assay only
c
Used in RT-qPCR for total transcript quantification
b

Table 3.3. Primers and probes used in ChIP and RT-qPCR analysis
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(34)
(34)
(34)
(34)
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Summary
As an important human pathogen, HCMV possesses many essential genes whose
functions remain unknown. In this dissertation, I characterize the function and potential
mechanism of a novel essential protein pUL79 during viral infection.
To characterize the function of pUL79 during viral infection, we applied the ddFKBPmediated, Shield-1-regulated protein genetic approach(3) to investigate its role during
HCMV replication(20). Without pUL79, HCMV failed to replicate. Systemic analysis of
ADddUL79 infection in the absence of Shield-1 showed that UL79 was required at late
stages of HCMV infection. Acting as a viral early-late protein, pUL79 localized into viral
replication compartments where viral replication and late gene transcription took place. In
the absence of pUL79, the immediate-early and early viral proteins as well as viral DNA
accumulated normally. However, accumulations of viral late transcripts and proteins were
dramatically reduced. We conclude that UL79 acts as a viral transactivator after DNA
replication to promote the accumulation of late viral transcripts.
To further dissect the potential mechanisms of pUL79 to regulate viral late gene
expression, we applied an unbiased proteomic analysis to identify its protein partners. In
chapter 3, we showed that HCMV pUL79 interacts with human RNAP II as well as other
viral factors involved in late gene expression during viral infection. Since HCMV genes are
transcribed by RNAP II during viral infection, we focused on the nature of the pUL79-RNAP
II interactions, finding that pUL79 does not alter the protein levels of RNAP II or its
recruitment to viral promoters. However, during late times of infection, pUL79 helps RNAP
II to efficiently elongate along the viral DNA template to transcribe HCMV genes. While
viral genes were regulated in this manner, we found that host genes are not regulated by this
pUL79-mediated mechanism. Therefore, our study identifier a previously uncharacterized
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mechanism in which RNAP II activity is modulated by the viral factor pUL79, and
potentially other viral factors as well, for coordinated viral transcription.
Altogether, our significant finding is that pUL79 plays a critical role to drive viral late
transcription after viral DNA replication. Since pUL79 is functionally conserved among
beta- and gamma- herpesviruses, this provides an opportunity to understand the previously
uncharacterized regulation of viral late transcription of these two viral sub-families.
Inhibition of pUL79 and homologs represents a novel anti-viral therapeutic target against
both beta- and gamma- herpesviruses. Moreover, since the function of pUL79 is mediated by
its interaction with RNAP II, our study also serves as a novel probe to elucidate the
mechanistic actions of the RNAP II complex during transcription initiation, elongation, or
potentially termination.
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Future Directions
Although we have taken important steps to characterize the function of pUL79, the precise
mechanism by which pUL79 regulates HCMV late gene transcription awaits further
investigation. Below we discuss future experiments that may aid in this discovery.

How does pUL79 specifically regulates transcription of viral loci during late times of
infection? In chapter 3, we show that pUL79-mediated transcriptional regulation is limited
to viral but not host genes. The transcription rates of the host genes investigated, including
GAPDH and RPL30, were not regulated by pUL79 (Figures 3.6F and 3.6G). Consistent with
these results, RNAP II did not stall on the GAPDH locus in the absence of pUL79 (Figure
3.4). We suspect that the specific regulation of viral genes by pUL79 may be partially due to
its localization. pUL79 is enriched in the replication compartments where late viral
transcription occurs, which suggests that pUL79 primarily associates with RNAP II
transcribing viral genes(20). A recent study showed that the viral late promoters encode a
non-canonical TATA box sequence that is well-conserved among late promoters of beta- and
gamma-herpesviruses(9). EBV BcRF1, homolog of HCMV pUL87, is a viral TATA-box
binding protein which preferentially bound to this non-canonical TATA box over the
canonical sequence, suggesting that the viral transcription machinery directs RNAP II to viral
late promoters during late stages of viral infection(9). In HCMV, multiple characterized viral
late promoters also encode the same non-canonical TATA sequences which may allow for
the targeting of RNAP II to their loci(8, 11-14, 16, 23). However, in the absence of pUL79,
we also observed an overall drop in transcription rates among all different kinetic classes of
viral genes during late times of infection (Figure 3.6). For example, UL54 is an early-late
gene with a classical TATA sequence(12, 13). However, the transcription rate of UL54 still
decreased in the absence of pUL79 (Figure 3.6C). We hypothesize that, during late stage of
!
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viral infection, BcRF1 and its homologs (ex. pUL87 in HCMV) are expressed and form
complex with pUL79 homologs. This viral protein complex, located in the viral replication
compartment, replaces host TBP and other RNAP II associated factors to direct RNAP II
transcribing viral genes belong to different kinetics. However, the binding preference of
BcRF1 promotes RNAP II to transcribe more viral early-late and late genes during late times
of viral infection. Further characterization is needed to dissect how pUL79 associates with
these viral factors to regulate the rate of viral transcription.

How does pUL79 modulate RNAP II elongation? We considered two potential roles that
pUL79 might play. First, pUL79 might act as a modulator to increase promoter clearance, a
step in which RNAP II transfers from the initiation state to the elongation state. During the
transcription cycle, RNAP II is recruited to promoters by host TATA-box binding protein
(TBP) and other general transcription factors (GTFs) to form the pre-initiation complex
(PIC). The PIC helps position RNAP II over transcription start sites, denatures DNA, and
positions DNA into the RNAP II active site for transcription(5). After transcription initiates,
the RNAP II dissociates from PIC and recruits elongation factors for efficient transcription.
The dissociation of RNAP II from PIC is mediated by TFIIH and other cellular kinases to
facilitate exchange between initiation factors and elongation factors(1, 25). Inefficient
dissociation reduces the rate of RNAP II elongation with subsequent failure to transcribe
genes(1). Several viral proteins have been shown to be viral transcription initiation factors
and to potentially form a unique viral PIC. For example, UL87 and its homologs in beta- and
gamma- herpesviruses were found to be viral TBPs and regulate late transcript
accumulation(2, 9). MHV68 ORF30 and ORF34, homologs of HCMV UL91 and UL95,
were also shown to be required for RNAP II recruitment to viral late promoters(24). EBV
Rta, a homolog of CMV UL112/113, was found to associate with viral late promoters during
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late times of viral infection (10). All of these viral factors might participate in viral PIC
assembly by mediating RNAP II promoter positioning (Figure 3.7A). Strikingly, pUL79 copurified with the factors mentioned above (Table 3.1). In the absence pUL79, the recruitment
of RNAP II to viral promoters was not influenced, indicating that pUL79 is not required for
RNAP II initiation (Figure 3.4). However, the elongation rates of RNAP II at viral loci
dropped, suggesting that pUL79 is essential for certain transcription steps downstream of
initiation. Since the viral PIC complex might not be recognized by host dissociation factors,
we hypothesize that pUL79 plays a role in the release of RNAP II from viral PIC prior to
elongation. The simplified model is shown in Figure 3.7A. To test this hypothesis, further
analysis is required to determine the composition of RNAP II/viral PIC as well as their
distribution on the viral DNA.
Second, pUL79 could play a role in the epigenetic regulation to modulate viral
transcription. Previous studies showed that HCMV undergoes dedicated histone modification
during infection, including increases in histone 3 acetylation (H3Ac) and histone 3 lysine 9
(H3K9) methylation, that activate gene expression(17). After the onset of viral DNA
replication, newly synthesized viral DNA is wrapped with histone 3 lysine 4 methylation
(H3K4me2), a modification that favors active transcription, suggesting that epigenetic
regulation is involved in viral late transcription(18). However, pUL79 was not required for
methylating H3K4(18). Notably, we showed that the rate of RPL30 transcription is not
regulated by pUL79 (Figure 3.6G). RPL30 is a host ribosomal protein whose epigenetic
modification was similar to viral DNA during late times of viral infection(18). Therefore, if
pUL79 is an epigenetic reader for late viral transcription, it might recognize an as of yet
uncharacterized histone modifications unique to viral DNA. We hypothesize that pUL79 act
as an epigenetic reader to recognize these unique modified histones and unwrap viral DNA
packaged by histones to facilitate RNAP II elongation (Figure 3.7B).
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How does pUL79 interacts with RNA polymerase II (RNAP II) complex? To determine
how pUL79 interacts with RNA polymerase II, we created truncation mutants targeting Nterminus and C-terminus of pUL79 (Figure 4.1A), and tested the ability of mutant pUL79
proteins to interact with RNAP II in 293T cells (Figure 4.1B). Both mutants were expressed
at 293T cells. However, N-terminal truncation mutant had lower expression level, suggesting
that the N-terminus of pUL79 might be required for proper protein folding and stability. As
expected, full-length pUL79 co-immunoprecipitated with RNAP II. In contrast, both N- and
C- terminuses mutants were unable to do so. We concluded that both N- and C- terminuses
of pUL79 are required for pUL79-RPB1 interaction. To further explore how pUL79 interacts
with RNAP II complex, we decided to focus on RPB1, the largest subunit of RNA
polymerase II complex, with the help of bioinformatics tools.
In chapter 3, we identified RPB1 as one of pUL79 interacting partners. RPB1 plays a
major role in the RNA polymerase II transcription cycle. The C-terminal domain (CTD) of
Rpb1 functions as a binding platform for the recruitment of transcription-associated factors.
During the transcription cycle, the Rpb1 CTD undergoes dynamic phosphorylation that
defines the ability of the RNA pol II transcriptional complex to recruit the appropriate set of
mRNA-processing and histone-modifying factors(4, 6). The pUL79-RPB1 interaction
suggests that pUL79-regulated RNAP II transcription elongation might be mediated by this
interaction. To test this hypothesis, we performed bioinformatics analysis (MAFFT program)
to identify the potential domain of pUL79 required for binding to Rpb1. We found that
pUL79 potentially has conserved domains similar to a CTD-interacting domain (CID) present
in proteins such as Pcf11 and SCAF4/8, which are essential and evolutionarily conserved
factors for polyadenylation-dependent and -independent 3’-RNA processing, respectively(7,
15) (Figure 4.2A).
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To confirm this finding, we first created pUL79 mutants that contained an internal
deletion covering the CID-like domains (pUL79 del aa. 40-46, del. aa. 96-103, del. aa. 192200, see Figure 4.1). We examined their ability to complement pUL79 null virus and interact
with Rpb1. All three mutants failed to complement the growth of pUL79 null virus or rescue
the defect in late protein accumulation (Figure 4.3). We also performed coimmunoprecipitation experiments to test the interaction between Rbp1 and these pUL79
mutants. The preliminary study also suggests that all three mutants fail to interact with Rpb1
during virus infection (Figure 4.2). However, we noticed that these pUL79 mutant proteins
were expressed at low levels, suggesting that the internal-deletion mutants might be unstable
and degraded. To overcome this, we created two different pUL79 mutant libraries. First, we
created additional internal-deletion mutants before and after the CID-like domains. We
expected that these mutants would serve as controls and help us understand whether the CIDlike domains are critical for protein folding and stability. Second, we created site-directed
mutagenesis mutants covering most of the three CID-like domains that might avoid protein
stability issues and allows us pinpoint the critical residues of protein interaction. The
preliminary results of complementation tests show several loci within or outside CID-like
domains are important for viral growth (Figure 4.4B and 4.4C). However, we noticed that
several pUL79 mutant proteins, even when expressed at similar levels compared to the wildtype pUL79, failed to translocate into nucleus (Figure 4.4D). Further analyses are required to
define whether these regions are critical for proper protein folding to pass through nuclear
pore. Meanwhile, further analyses, including co-immunoprecipitation and in vitro binding
assays, will help to confirm whether and how pUL79 interacts with RNAP II complex
through RPB1 CTD domain.

!

119!

Interactions between pUL79 and viral DNA replication factors. During lytic infection,
HCMV genes are expressed in a highly ordered temporal cascade. The transcript
accumulation of early genes is independent of viral DNA synthesis; however, the continued
accumulation of a subset of these genes (i.e, early-late) at late times is enhanced by the onset
of viral DNA synthesis(22). Following viral DNA synthesis, late viral genes start to
transcribe. In chapter 2, we showed that the pUL79-mediated viral transcription requires
DNA replication(20). Over-expression of neither pUL79 alone nor the combination of all
late gene regulators currently identified in cells altered the expression kinetics of viral genes,
especially viral late genes(19, 20). In chapter 3, we found that pUL79 co-purified with viral
DNA replication factors. It is possible that viral DNA replication directs viral late
transcription through the direct interactions between replication factors and pUL79.
Interestingly, a recent study of the HCMV latent transcriptome in CD14+ and CD34+ cells
showed that pUL79, pUL87, pUL95 were consistently expressed in latently-infected
cells(21). Further analysis will help to determine whether and how these beta-gamma genes
(pUL79, pUL87, pUL92, or pUL95) act as sensors of viral DNA replication to direct late
transcription during acute infection and viral reactivation during viral latency.
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A. Viral protein expression profile and virus viability of over-expressing pUL79 wild-
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